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Summary of the project 
Background: It is important to obtain robust scientific information on possible safety 
concerns related to the use of drugs during pregnancy in post-approval settings. Since 
pregnant women are actively excluded from trials in the clinical development of most 
products, at the time of the drug entry in the market meaningful human data on the effects 
of that drug during pregnancy are rarely available. There are approximately 5 million 
pregnancies in the EU each year, and about 1 in every 10 women of childbearing age is 
pregnant each year. Insufficient information for management of maternal disease during 
pregnancy can have teratogenic impact on fetus. 
Aim and objectives: This reach comprises three studies, in the first study; the goal was 
to evaluate the maternal use of medicines and the associated risks of cleft lip and/or 
palate in fetus and to link this to the accuracy and currency of safety information available 
in prescribing information. The second area of research was aimed at identifying and 
exploring social and digital media to understand patients’ experiences regarding medicine 
use during pregnancy. Last, but not least, I contributed to the development of an 
enhanced pharmacovigilance programme for analysing drug exposure during pregnancy 
and outcomes in neonate. 
Method: Firstly, I identified medication-induced risk factors for oral clefts with safety 
signal detection and safety signal evaluation techniques. Then I assessed the 
completeness of the safety information for pregnancy exposures in the Summary of 
Product Characteristics and the Patient Information in the UK and the US.  
In second study, the content of posts concerning pregnancy and use of medicines in 
online pregnancy forums was analysed using artificial intelligence in the form of natural 
language processing and machine learning algorithms.  
Third, the PRIM (PRegnancy outcomes Intensive Monitoring) system was developed as 
an enhanced pharmacovigilance data collection method. This was used to improve the 
quality and content of prospective case reports using sets of targeted checklists, 
structured follow-up, a rigorous process of data entry and data quality control, and 
programmed aggregate analysis.  
Results: For 12 antiepileptic drugs studied there was a statistical disproportionality in 
individual case safety reports indicative of an increased risk of cleft lip and/or palate. 
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There are inconsistencies between the UK and US safety labels, despite the same 
evidence being available for assessment. 
The second study showed that in social media forums many pregnant women with MS 
shared profound uncertainties and specific concerns about taking medicines during the 
reproductive period. There was evidence of concealment of information with health care 
professionals; however, the same evidence was shared with a peer group. 
The PRIM method of enhanced pharmacovigilance has yielded substantially more 
information on the safety of fingolimod exposure during pregnancy than has been 
achieved via the regulatory authority-mandated pregnancy registry. 
Conclusion: Use of medicines during pregnancy is an important topic for public health. 
There is a significant need to provide inclusive, unbiased, up to- date information to 
prescribers and women of childbearing age concerning the use of medicines in pregnancy 
and postpartum during breastfeeding. Information must be provided in a timely manner 
by a trusted source and patients should have access to health care professionals with the 
relevant expertise and knowledge. It is important that the full anonymised data set, along 
with evidence-based conclusions are made publicly available to inform decision-making. 
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1. Introduction  
1.1 Medicinal product development 
Development of human medicinal products follows a highly regulated process prior to 
marketing authorisation. Controlled clinical trials are conducted in a rigorous and 
organized way in order to generate substantive medical data in support of a marketing 
authorization application. This involves systematic data collection and analysis of efficacy 
safety and quality of the medicine (see Figure 1). Although the controlled clinical trials are 
considered as standard for providing efficacy and safety data, the available data for safety 
from these trials have known limitations such as: 
• Limited study sample size compared to real world patient population 
• Limited exposure time 
• Exclusion of high-risk patients such as: 
o Patients with organ impairment (e.g. hepatic dysfunction, renal 
dysfunction)  
o Paediatric and geriatric patients, and  
o Pregnant and breastfeeding women 
Therefore, to overcome these limitations it is necessary that the marketing authorization 
holder (MAH) for a medicine and the health authorities continue monitor the safety of a 
medicine after approval and throughout the post-marketing or Phase IV period.  
 
Figure 1. Drug Discovery and Development process 
Source available at https://doctortarget.com/machine-learning-applied-drug-discovery/ Internet Accessed Oct 2019 
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1.2 Definition of Pharmacovigilance by the World Health Organization 
Pharmacovigilance (PV) is defined by the WHO as”…the science and activities relating 
to the detection, assessment, understanding and prevention of adverse effects or any 
other drug-related problem. The aims of PV are to enhance patient care and patient safety 
in relation to the use of medicines; and to support public health programmes by providing 
reliable, balanced information for the effective assessment of the risk-benefit profile of 
medicines…’’ (1). The WHO originally established its Programme for International Drug 
Monitoring in response to the thalidomide disaster detected in 1961. 
Pharmacovigilance begins during phase I clinical trials and translational studies; PV 
continues after the drug is authorised for marketing. Due to the different limitations of 
clinical trials, the complete safety profile of a drug cannot be fully assessed before 
marketing. Post-approval adverse reactions represent a major public health problem; 
causing or contributing to up to 5% of hospital admissions, around 28% of emergency 
visits, and approximately 5% of hospital deaths; the associated costs amount to an 
estimated seventy-five billion US dollars annually (2,3). Thus, MAHs, national bodies and 
government agencies such as the US Food and Drug Administration (FDA), the European 
Medicines Agency (EMA), and international organizations such as the World Health 
Organization (WHO) have expanded their pharmacovigilance activities in various ways. 
For example, in the U.S., post-marketing surveillance of medicines occurs actively via 
Phase IV studies and passively with voluntary and mandatory reporting through to the 
FDA’s Adverse Event Reporting System (FAERS), e.g. using MedWatch forms, and the 
Institute of Safe Medication Practices Medication Error Reporting System (MERP) (4,5). 
The MedWatch program allows the public including patients and HCPs to report adverse 
events that they suspect are related to medical treatment. Reporting by the public is 
voluntary via a mobile app or webpage, whereas reporting of suspected adverse reactions 
is mandatory for manufacturers (3).  
In the European Economic Area, the EudraVigilance is a system implemented for 
managing and analysing information on suspected adverse reactions to medicines that 
have been authorised or are being studied in clinical trials . The EMA is responsible for 
operating the system. This PV system is described extensively the EMA PV system 
manual (6) and it covers the organisational structure, responsibilities, procedures, 
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processes, appropriate resource management, compliance management and record 
management (7). (See Figure 2) 
In the past, most PV activities at pharmaceutical companies were focused on the handling 
of adverse event case reports also called individual case safety reports (ICSRs). 
Currently the main PV activities are focused on systematic data collection, collation, 
analysis, expedited and aggregate reporting of adverse events, signal detection, signal 
management, and risk management planning and mitigation. Bearing in mind that 
generally all PV activities and systems including handling of ICSRs and timely reporting 
of these cases to the regulatory authorities are highly regulated (8). There are several 
guidelines published to ensure standardisation, reporting compliance and quality 
including but not limited to the  Good Pharmacovigilance Practice (9), the EMA PV system 
manual (6) and the International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use (ICH) E2B R3 guideline for uniform format of 
exchanging and transmission of ICSRs (10). 
 
Figure 2. Post-marketing reporting system- Eudravigilance system overview  
Source available at: https://www.ema.europa.eu/en/human-regulatory/research-
development/pharmacovigilance/eudravigilance/eudravigilance-system-overview 
Internet accessed on 4.Nov.2019.  
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1.3 History - What we know about Thalidomide today?  
 
‘’The further you can look back, the longer you can look forward’’ 
Winston Churchill, Royal College of Physicians, 1944 
The well-documented tragedy of birth defects that occurred after in utero exposure to 
thalidomide in the late 1950s and early 1960s. It affected tens of thousands of children, 
many of whom were born with severe birth defects (11) (See Figure 3). 
 
Figure 3. The relationship between the sales of thalidomide (broken line) and the 
number of malformations of thalidomide (solid line)  
Source: Lenz W: Discussion in Symposium on Embryopathic Activity of Drugs. Robson JM, Sullivan FM, Smith RL(eds): Eur J Obstet 
Gynecol Reprod Biol 16:365, 1984. 
The thalidomide disaster completely changed the way medicinal products were tested 
and authorised, particularly in respect of their safety profiles. After the thalidomide 
scandal, regulatory agencies and their advisory scientific bodies focused on the 
importance of rigorous and relevant testing of pharmaceutical medicines, biologicals and 
vaccines prior to marketing authorisation (12). Later on, many studies were conducted to 
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understand different aspects of thalidomide-induced teratogenicity and three main topics 
were discussed. 
‘’Poetry is what is lost in translation’’ 
Robert Frost (1847-1963) 
The initial studies showed the different sensitivity between species of animal models 
related to drug exposure. Data for thalidomide showed that rat experiments had not 
produced malformations comparable to those which were evident in humans. As a result, 
developmental toxicity testing for pharmaceuticals was extended, such that 
manufacturers were obliged to conduct reproductive toxicology testing in at least two 
species, one of which was not a rodent. In 1966, the FDA laid the foundation for the 
development of the segment I (fertility and general reproduction), II (teratogenicity), and 
III (perinatal) testing protocols. The aim was to address potential developmental and 
reproductive toxicities of pharmaceuticals. Prior to the development of these three 
segments of the testing protocols, toxicology testing was more hypothesis-driven rather 
than the systematic bioassay testing strategy that is in place today. Even today, it is 
known that the results provided from animal models do not always translate faithfully to 
humans, in valproate, as there is no qualified animal model for autism (13) and it is 
impossible to model ‘low IQ’, as far as I am aware.  
Secondary key findings from further studies on thalidomide exposures emphasized the 
importance of the timing of exposure of the mother and the embryo in relationship to the 
period of organogenesis. As most organs and systems develop during the first trimester, 
exposure to any potentially teratogenic agent at that time carries the highest risk of major 
congenital malformation as an outcome. For individual organ systems, the periods of risk 
are quite specific (see Figure 4). 
Thalidomide causes embryopathy in a relatively breif, time-sensitive window, which 
extends approximately between day 20 and day 36 after fertilization (around 34–50 days 
after last menstrual period) (14). It is recognized that central nervous system development 
continues into the second and third trimesters, therefore effects on fetal growth and 
development may occur as a result of exposure in these later phases of pregnancy (15). 
Exposure in late stage of pregnancy and near-term carries the greatest risk related to 
functional neonatal health and development, such as neonatal toxicity following maternal 
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use of opioid analgesics or maternal neonatal withdrawal effects following maternal use 
of selective serotonin reuptake inhibitors (15). Pregnancy exposure to benzodiazepines 
in third trimester resulted in infants born either with the floppy infant syndrome, or neonatal 
withdrawal symptoms (16). 
 
Figure 4. Stages of human embryo-fetal development  
Source: available at https://basicmedicalkey.com/special-aspects-of-perinatal-pediatric-pharmacology/ Internet 
accessed Oct. 2019. 
Last but not the least, the mechanism of action of thalidomide is directly related to the 
pattern of congenital anomalies observed; in 1998, FDA approved thalidomide use for the 
treatment of Behçet’s disease, Hansen’s disease, and multiple myeloma. As an anti-
angiogenic drug, thalidomide inhibits tumor hyper-vascularity, thereby inhibiting tumour 
growth, and metastasis (14). These properties of thalidomide, which confer significant 
toxicity to the human embryo have been clearly demonstrated to be specifically valuable 
in the treatment of multiple myeloma (14). Prescription and use of thalidomide is carefully 
monitored using the System for Thalidomide Education and Prescribing Safety_program 
(17) which enforces the monitoring of patients to ensure they are not pregnant while 
receiving treatment. However, despite the very best efforts of pregnancy prevention 
15 
 
programmes and the provision of additional risk minimization measures the diversion of 
supply has occurred into South America, leading tragically to a new generation of 
thalidomide-exposed babies which occurred predominantly in Brazil (14). Thalidomide is 
used to treat complications of Hansen’s disease in Brazil, as it is endemic in this area. 
Unfortunately, the product is given to patients who share the medicine with others, many 
of whom do not possess or understand the prescribing information (which is often written 
in English). A substantial cohort of patients are not informed of the dangers of taking 
thalidomide in pregnancy, hence a second cohort of children have been born with similar 
major congenital malformations to the phocomelia and amelia seen in children exposed 
to thalidomide in utero between 1957 and 1962 (14). 
It is important to understand the mechanism of action of teratogens, as malformations 
may occur across structurally-related pharmaceuticals within a particular class of 
medicines. In addition, more effort is required for global and national PV systems to 
coordinate their efforts concerning pregnancy prevention programmes, as well as to put 
a strong emphasis on the provision of effective risk communication via simple, direct 
pathways. For example, a visual warnings being placed not only on the outer packaging 
and on patient information leaflets, but also imprinted over each blister cell of a medicine. 
Pictograms, which can be understood without reference to extensive text, could be 
applied globally in case pack inserts are not translated, or are not required or provided 
with the medicine. 
 Based on animal models (both in vitro and in vivo) there is still no completely reliable 
method , to predict and much less to prevent potential teratogenic effects of medicines. 
Therefore, there is a huge importance applied to the careful collection, collation, 
investigation medical evaluation of data concerning human pregnancy exposures as soon 
as marketing occurs. A systematic approach to data management and signal detection 
can provide more comprehensive data in this field, and thereby yield important safety 
information for communication to patients, healthcare professionals, carers, regulatory 
authorities, manufacturers and indeed all stakeholders in public health. (See Figure 5) 
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Figure 5. Risk communication in Pharmacovigilance 
 
1.4 Pregnancy and maternal disease control 
In the European Union (EU) more than 5 million women become pregnant each year (18). 
Evidence suggests that almost 75% of women take at least one medication during 
pregnancy (19). Besides the short-term use of prescription-only medicines (e.g. for severe 
nausea or urinary tract infection) during pregnancy, use of over-the-counter products (e.g. 
for headache, coughs and colds) there is also a need for the treatment of chronic illnesses 
(e.g. epilepsy, multiple sclerosis, inflammatory bowel disease) during pregnancy (18). 
Nowadays, with the trend of women becoming pregnant later in life and with the 
increasing occurrence of certain chronic diseases such as obesity, diabetes, epilepsy, 
hypertensive heart disease, multiple sclerosis and systemic lupus erythematosus, more 
pregnant women require medication for treatment of pre-existing conditions throughout 
pregnancy. Uncontrolled disease during pregnancy can lead to irreversible harm to the 
mother and the embryo or foetus. Globally, almost 44% (90% uncertainty interval [UI] 42–
48) of pregnancies are unplanned (20), which could result in potential unintended 
exposure to medicinal products in pregnancy when a woman may not be aware she is 
pregnant.  
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Since the thalidomide tragedy over half-a-century ago, the potential teratogenic effects of 
medicines have been a cause of distress in pregnant women and have provided a 
challenge to prescribers. Incomplete information may affect the willingness of physicians 
to prescribe medicinal products and patients may be reluctant to take  prescriptions to the 
pharmacy. Even if the prescription is dispensed and accepted by the patient  there may 
be limited adherence to the prescribed dose of medicine (15). 
Pregnancy is a specific phase of life that requires special care in every aspect particularly 
from a therapeutic point of view. Prescribers are generally taught to select the safest, 
most effective medicinal product available, and assess the benefit–risk at an individual 
patient level before providing a prescription. The concern of the mother cannot be dealt 
with in isolation, rather the prescriber must consider the mother and child as a ‘’maternal 
placental-fetal triad’’. A maternal placental-fetal triad together with pharmacokinetic and 
pharmacodynamic information should be considered for all therapeutic interventions in 
pregnancy including active treatment, maintenance therapy and prophylaxis (21). The 
majority of medicines and/or their metabolites can cross the placenta, and the 
pharmacokinetics of many human medicinal products are altered during pregnancy, 
potentially affecting efficacy and safety. Despite this at the time of authorisation little 
information is usually known about an individual drug and its effects on the human embryo 
or fetus (15). Therefore, the maternal benefit–risk assessment might be very different from 
the benefit-risk assessment for non-pregnant women or men.  
The primary target of therapeutic treatment in pregnancy is the mother; the fetus is 
essentially an unwanted secondary recipient. Exceptionally in a few disease areas, such 
as in the treatment of HIV infection, the fetus is the target (22). Any adverse effects of 
treatment may be sustained throughout pregnancy and even into the early life of the 
neonate, with long-lasting pharmacodynamics (e.g. B cell depletion in newborn exposed 
to immunosuppressant in utero), and the possibility of drug exposure via breast milk. In 
exceptional cases the adverse effects on the fetus may be of very long latency (e.g. 
neurodevelopmental delay with sodium valproate which evident several years after 
exposure (23)) and vaginal cancer with diethylstilbestrol (DES) (24). The daughters of 
women who used DES while pregnant—commonly called DES daughters—have about 
40 times the risk of developing clear cell adenocarcinoma of the lower genital tract than 
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unexposed women (25). Research has shown that the risk of developing this disease 
remains elevated as women age into their 40s (24,25). 
Risks to the foetus, however, need to be assessed against the benefits of treatment for 
the mother from the perspective of necessary maternal disease management and good 
health. In the UK, it has been reported that underlying maternal conditions are more likely 
to cause maternal deaths than direct pregnancy complications (26). It is incumbent upon 
the prescribing physician to assess the secondary effects of the disease on the embryo 
or fetus, and weigh the benefits and risks of the medicinal treatments that may be 
indicated. Equally, it is important that information is provided to the patient, so that an 
informed decision can be made. 
Many chronic conditions are treatable, and adverse outcomes can often be prevented by 
providing the necessary care and carefully selected medical treatment. A meta-analysis 
of adverse perinatal outcomes in women with asthma showed that poor asthma control 
during pregnancy increases the risk of preeclampsia, predisposes the neonate to low 
birthweight and is associated with prematurity (27). Similarly, it is well recognized that 
babies born to women with pre-pregnancy diabetes are at a significant increased risk (by 
two to three fold) of giving birth to a child with congenital malformations. These risks are 
reduced in diabetic women who achieve good glycaemic control before conception and 
during the entire pregnancy (28,29). However, often there are insufficient data available 
for fully informed decision-making. As few as 5% of available medicines have been 
sufficiently tested, monitored with well-informed, accurate and up-to-date labelling 
concerning administration of the product to pregnant or breastfeeding women. On 
average, it takes almost 27 years to determine an appropriate label that accurately 
communicates the teratogenic risk of medicine (30).  
During clinical development of most drugs and biological products, pregnant women are 
actively excluded from trials, and pregnancy prevention measures are routinely specified 
in study protocols, along with routine pregnancy testing where applicable. If pregnancy 
does occur during a trial, the patient is classified as a protocol violator, and according to 
standard procedure must discontinue study medication and will be monitored for outcome 
of pregnancy, if carried to term. For example, a study reported 66 human pregnancies 
during the clinical development program of fingolimod in multiple sclerosis. Of these 66 
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pregnancies, there were 24 elective terminations, 28 live births, 9 spontaneous abortions 
and 4 ongoing pregnancies and one unknown outcome (31). Hence, the number is small 
to allow any conclusive interpretation. Consequently, at least initially, safety information 
provided to prescribers and patients at the time of authorization is based on nonclinical 
reproductive toxicology studies. It is recognized that even major congenital 
malformations, such as those that occurred with thalidomide, do not invariably appear in 
all animal species (12), nor do they always translate from animals to the clinic. The 
overwhelming majority of the evidence of the teratogenic potential of medicines is gained 
via post-marketing monitoring (32). 
The WHO recommends exclusive breastfeeding for infants up to six months of age for 
optimal growth, health and development (33). Yet there is almost no evidence-based 
information with little or no adequate well-controlled studies in humans to characterize 
safety of medicines exposure via human breast milk. 
This is particularly true of information related to lactation, and secretion of active 
pharmaceutical ingredients and metabolites into breast milk, where the rodent model 
which is in common use is generally considered to be suboptimal (34). With lack of 
scientific information, women may be advised not to breastfeed if they are taking 
prescription medicines, or a mother may decide to forgo postpartum treatment of her 
disease in favour of breastfeeding her baby. However, Safety of medicine during 
breastfeeding is out of scope of this PhD research and future research is required in this 
field. (Please refer to Direction of Future Research section of this thesis). 
There is an important need for safety information on the outcomes of exposure to 
medicinal products during human pregnancy and when breastfeeding. 
The availability of more detailed, consolidated, medically-evaluated and  trustworthy 
information related to safety of medicines used in pregnant and breastfeeding women 
could help the HCP and mother in making evidence-based decisions leading to an 
improvement in outcomes for both the mother and the baby. 
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1.5 Cleft lip and/or palate  
1.5.1 Epidemiology 
Cleft lip and/or palate (CL/P) are congenital malformations that occur in the embryonic 
and early fetal stages (35). Cleft lip or palate affects one in about every 700 newborns 
globally (36,37). Patients with this deformity require short-term and long-term care as well 
as medical and often surgical follow-up from practitioners in multiple specialties. Patients 
may need multiple surgical interventions from infancy to adulthood, in order to obtain an 
optimal outcome relative to speech, occlusion, facial appearance, and personal self-
esteem. When taken together these interventions represent a great burden to the health 
care and social support systems in terms of cost and effort. There is also a potentially 
significant impact on the mental well-being of the patient, which may require counselling 
and further medical interventions including medical treatment. 
1.5.2 Embryology and developmental physiology of cleft lip and palate  
Cleft lip when it occurs is established in the first 6–8 weeks of pregnancy. It is usually 
considered to be caused by failure of the fusion of the maxillary and median nasal 
processes. It may also be caused by incomplete mesodermal in-growth into these 
processes, with subsequent breakdown of epithelium (35). A palatal cleft results from the 
failure of fusion of the palatal shelves of the maxillary processes (which normally occurs 
between 8th to 12th weeks of pregnancy). These shelves are initially separated by the 
tongue, which descends by the eighth week of pregnancy, allowing the shelves to fuse 
(35). 
1.5.3 Classification of cleft lip and palate  
Several methods of classification have evolved. The most accurate classifications are 
based on the system recommended by Kernahan & Stark, which describe the various 
forms of cleft lip and palate as follows (38):  
• Unilateral, bilateral or median;  
• Complete or incomplete (involving soft palate)  
Based on the aetiology of this congenital anomaly, CL/P can be classified as syndromic 
and non-syndromic. Non-syndromic cleft lip with or without palate is the most frequent 
craniofacial malformation. Single nucleotide polymorphisms within nineteen loci  (each 
21 
representing a genetic variant) have been associated with non-syndromic CL/P in 
genome-wide association studies of European individuals (39). Around 70% of CL/P 
cases are non-syndromic (36). There are also more subtle variants of the morphology of 
the lips and face in unaffected individuals due to the more common genetic variants. 
1.5.4 Aetiology cleft lip and palate  
The precise aetiology of CL/P is unknown but it has been hypothesized that it may be due 
to a combination of genetic and exogenous factors such as maternal smoking and alcohol 
consumption, in utero exposure to certain chemical and medicines (40).  
Association of folate, vitamin B6 and zinc deficiency during gestation and CL/P have been 
reported in animal and human studies. Folate deficiencies in early pregnancy are reported 
with an increased risk of CL/P (38). Other genetic factors that may affect the presence of 
orofacial clefts include the maternal ability to maintain red blood cell zinc concentrations 
and myo-inositol (a hexahydrocycyclohexane sugar alcohol) concentrations (41).  
Maternal ability to maintain adequate levels of Vitamins B6 and B12 and fetal ability to 
utilize these nutrients have also reported as a factor in the development of oral clefts 
(41,42). When these nutrients are not metabolized properly, errors in DNA synthesis and 
transcription may occur (42). Recent publications have focused on a possible genetic link, 
for example non-syndromic cleft Lip and palate polymorphisms affect normal lip 
morphology (39).  
One proven cause of CL/P is the maternal use of certain medicinal products. Clear causal 
associations have been established between drug treatments including anticonvulsants, 
such as valproic acid, phenytoin and phenobarbital, and the vasoactive drug isotretinoin 
and an increased risk of CL/P (38,43–45). Even though these medicines have been 
identified as important causes of CL/P, only limited attempts have been made to evaluate 
the possible associations between exposure to a broad range of medicinal products 
during pregnancy and the occurrence of CL/P in the offspring. Moreover, the mechanisms 
and pathways conferring teratogenic effects are uncertain at the present time; this 
requires further research. It is suggestive that maybe the teratogenic effect is because of 
alteration in vitamin K metabolism, folate deficiency to a reactive toxic intermediate 
(epoxide), apoptosis and hypoxia-reoxygenation damage (46). 
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2. Background - Data collection and analysis of pregnancy 
exposure to medicines 
2.1 Pre-Clinical reproductive toxicity 
As mentioned above, one of the regulatory requirements for authorisation of a medicinal 
product is successful completion of a range of animal toxicology studies, including 
reproductive toxicology. In some cases, the data generated from tests in animal models 
can provide a means to predict teratogenic effects in the clinic. However, many times, the 
results from reproductive toxicology studies may not translate into human risk because of 
significant variations in teratogenic response among species (47). In addition, animal 
toxicology studies are designed so that at least one dose tested will provoke an adverse 
toxic response. The results at those dose levels may not be predictive of those effects 
that might be observed at the intended therapeutic doses used in humans (48). 
2.2 Post-marketing surveillance method 
Health authorities such as the FDA in the US and the EMA in the EU often require the 
marketing authorization holder to conduct pregnancy safety studies as a condition of 
authorisation or after approval in the post-marketing phase (49). The ultimate goals are 
to further characterize risk of reproductive toxicity in human pregnancy and provide more 
information for prescriber and patients in the product’s label. Where a teratogenic risk is 
identified there may also be an obligation imposed on the MAH to communicate, inform, 
educate and to establish and maintain a pregnancy prevention programme. There are a 
number of surveillance methods including spontaneous reporting, solicited reporting, 
pregnancy (or product) exposure registries (50) and population-based surveillance 
studies such as using claim medical records and insurance claims (32). 
2.2.1 Pregnancy exposure registry 
Pregnancy registries are, in most instances, either product-specific or focused on a class 
of medicines. Registries have for decades been considered to be the preferred method 
to collect safety information on human exposure to medicines during pregnancy because 
they are designed to collect data prospectively on drug exposures during pregnancy. 
Often a pregnancy registry is required as a condition at the time of a new drug approval 
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especially when there is a safety concern or when there is a need to collect data on the 
use of the product in pregnancy based on the following circumstances (47): 
• Prior knowledge of the product suggests a safety concern based on the 
pharmacology or a class effect; 
• A teratogenic risk has been detected from animal studies or clinical trials data; 
• The product will of necessity be used during pregnancy where the potential 
benefits are likely to outweigh the risks (e.g. vaccines); 
• The product is likely to be used in women of childbearing potential (e.g. multiple 
sclerosis) 
• The product is primarily indicated for use in men, but is known to have adverse 
effects on the fetus (e.g. anti androgenic agents (51)) 
A pregnancy exposure registry is an observational prospective pharmacoepidemiological 
study to monitor the outcomes of pregnancies during which the mother or father was 
exposed to certain medicinal products. Participants are a cohort of women receiving a 
biopharmaceutical product(s) of interest as part of their routine clinical care and who are 
predominantly enrolled voluntarily during gestation, before outcomes are known. 
Pregnant women are followed until the end of pregnancy or longer to systematically 
collect information on specific pregnancy outcomes and compare to a scientifically valid 
reference population(s) (47). Some registries also permit intake of retrospective reports 
of pregnancies and outcomes, but it is well documented that there is a bias towards 
reporting of adverse outcomes when retrospective reporting occurs (52). 
The overall purpose of pregnancy registries is to provide human data on the safety of 
medicines during pregnancy (53). In many pregnancy registries, the primary objective is 
to assess the risk of major congenital malformations in the offspring of women exposed 
to the exposed drug immediately before conception or at any time during pregnancy. 
Ultimately, the aim is to determine whether the risk of a clinically important malformation 
in the neonate is higher or lower than expected in the unexposed population. Hence, this 
approach requires a careful study design, statistical analysis plan and well-written 
protocol to enable the research questions to be answered and objectives addressed. 
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Advantages of pregnancy registry:  
1. While approximately 50% of women reported taking at least one medication during 
pregnancy (54), the use of individual drugs for specific conditions (e.g. treatment of 
chronic diseases) is uncommon.  By enrolling an exposure group of women who 
took the medication(s) of interest, pregnancy registries can efficiently collect data 
on effects of rare exposures during pregnancy.  
2. Pregnancy registries usually have a longitudinal study design to observe  women 
during different stages of pregnancy. Often prospective pregnant mothers are 
considered for enrollment; before any prenatal tests have been performed and 
before information about the pregnancy outcome is known. This allows the 
estimation of absolute risks of pregnancy outcome and ascertainment of the 
exposure window.  Moreover, by performing several follow-ups with pregnant 
women detailed information can be obtained on exposure time in relation to 
gestational age, dose, frequency of medication use, as well as other variables. 
Thus, well-designed prospective registries can reduce exposure misclassification, 
recall bias, and confounding. 
3. Pregnancy registris can potentially collect data on variety of pregnancy outcomes 
(e.g. stillbirth, live birth, etc.) and infant outcomes including long-term data on infant 
health and development. It is recognised that long-term follow-up for adverse 
outcomes (e.g. neurodevelopmental delay) requires significant effort and 
investment (23). 
4. As part of the design of a protocol governing a registry, it could be required that 
each new born is examined by a physician to collect additional clinical data related 
to the outcome of interest. 
5. A pregnancy registry can be designed to compare the risk of outcomes among 
different groups including, monotherapies, polytherapy or population with no 
treatment. This information is useful to both women and treating physician for 
making informed decisions about whether to treat a condition during pregnancy and 
assess the alternate therapeutic strategies to use (47). 
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Limitations of Pregnancy Registries 
Unfortunately, many pregnancy registries fail to provide answers, or simply fail to operate 
as planned for a variety of reasons. The pregnancy registry approach has a number of 
limitations: 
1.  While registries are an efficient way to assess rare exposures, low numbers of 
case reports do not provide the required statistical power to detect rare pregnancy 
outcomes. 
2. Most pregnancy registries report the overall risk of major congenital malformation 
rather than a specific type of malformation. Pregnancy registries usually do not 
have sufficient sample size and/or power to evaluate increased risks for specific 
defects unless the relative risks are quite large or the cohort of exposed patients 
and adverse outcomes is disproportionately large. However, many drugs 
associated with adverse effects in pregnancy result in only small increases in rare 
outcomes (e.g. risk of CL/P reported for ondansetron (55)). Therefore, specific 
patterns of malformation maybe missed for the less potent teratogens. 
3. Identification of a comparator group (controls) may not always be feasible. The 
control group should ideally be closely matched to the exposed group so that both 
groups have the same baseline risk for adverse pregnancy outcomes. Matching 
cases and controls is particularly difficult for global registries that recruit exposed 
women from different countries with different backgrounds. 
4. Patient recruitment and retention are usually challenging. Moreover, due to 
voluntary participation in pregnancy registries the participants represent a small 
proportion of all women who have been exposed to a particular drug. For these 
reasons, the characteristics and experience of women who participate (e.g. more 
health conscious, higher socioeconomic status) in a registry may differ from those 
of non-participants, and these characteristics may modify the effect of the drug 
(e.g. a balanced diet in those patients who better understand nutrition and can 
afford a wider range of nutritious foodstuffs). 
5. Another important limitation of pregnancy registries is the length of time required 
to enroll sufficient numbers of exposed women to generate meaningful results 
(47).This timeframe maybe due to infrequent exposure in the general population 
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or methods and extent of recruitment efforts by the registry. Most registries run for 
many years before publishing any results, and even in these circumstances the 
results may never attain statistical significance. This extended period of evaluation 
before reaching conclusions can affect public health (47). 
6. Due to the long duration of registries, they are viewed as costly. 
7. Data from one pregnancy registry in a single country or region may not be sufficient 
to support a change in medical practice. However, if multi-national registries are 
implemented to address this challenge another limitation surfaces in that  the 
registry owner must first ensure homogeneity of design and operation of the 
registry across different medical cultures operating within different healthcare 
systems. The data owners must also agree beforehand how best to review pooled 
data from different centres in order to conduct meaningful analyses and to ensure 
that there is consistency of medical evaluations.  
2.2.2 Spontaneous case reports  
Collection of spontaneous reports of suspected adverse reactions is a legal requirement 
of all marketing authorization holders of medicinal products. Information on all pregnancy 
cases associated with exposure to a medicinal product (including exposure in the work 
environment such as at a manufacturing site for the active pharmaceutical ingredient 
(API) for which the marketing authorization holder has a pharmacovigilance responsibility 
is collected. (56,57). 
Good pharmacovigilance practice comprises comprehensive data collection on adverse 
pregnancy outcome to identify safety signal and develop a case series for analysis 
(50,58). Sources of pharmacovigilance data include spontaneous reports submitted to the 
MAH, competent authorities (including Swissmedic, the EMA and FDA) from consumers, 
healthcare professionals, including literature, at least some of which will result from 
clinical studies. ICSRs are most common source of reports of adverse pregnancy 
outcomes particularly if the pregnancy outcome is rare.  
The quality of ICSR and precise details of information reported (e.g. start date of 
medication(s), and the date of the last menstrual period) are critical for the evaluation of 
any potential causal association between the product and adverse outcomes. On some 
occasions, the competent authorities and some MAHs have considered a series of ICSRs 
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to be adequate and appropriate data sources for establishing a causal association 
between exposure and a specific congenital anomaly, such as for isotretinoin (59) or 
trastuzumab with serious adverse event such as oligohydramnios (60).  
Advantages of spontaneous reporting systems: 
1. Well-documented ICSRs can be used to identify safety signals specifically in rare
pregnancy outcomes. When supplemented by appropriate follow-up these ICSRs
may be used to characterise the nature of the adverse outcomes and for the
identification of potential risk factors (e.g. exposure in the first trimester).
2. Receipt of spontaneous reports is relatively higher when compared with enrolment
into registries (61), but it is recognized that significant under reporting occurs in
spontaneous reporting systems. (refer to 1 limitation below)
3. Because of 1 and 2, spontaneous reporting systems represent the best source to
generate hypotheses for safety signal detection and, depending upon the quality
of the data, ICSRs may contribute to the medical and scientific evaluation for the
detection of teratogenic effects.
4. To maintain drug safety surveillance for a long time, spontaneous reports are a
cost-effective source (62). This is particularly important where long-latency
adverse reactions are suspected, or where data must be collected over a
prolonged period in order to establish a meaningful sample size for analysis.
Limitations of spontaneous reporting systems: 
1. Under-reporting is one of the major drawbacks of spontaneous reporting systems
(63), HCP and consumers can voluntarily report suspected adverse reactions,
however, for a variety of reasons they do not necessarily report all cases of
potential reaction to the correct recipients. Deficiencies in post-authorisation
reporting of suspected adverse reactions are well documented (64–69). Professor
Bill Inman commented on the ‘seven deadly sins’ which in his view contributed to
under-reporting in the UK (64). Inman’s hypothesis was that the following were the
main reasons for the under-reporting of adverse drug reactions (ADRs):
• Ignorance ('I am unsure how to report an ADR')
• Diffidence ('I may appear foolish about reporting a suspected ADR')
• Fear ('I may expose myself to legal liability by reporting an ADR')
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• Lethargy ('I am too busy to report ADRs') 
• Guilt ('I am reluctant to admit I may have caused harm') 
• Ambition ('I would rather collect cases and publish them') 
• Complacency ('only safe drugs are marketed') 
Some of the above are speculative, and despite a grain of truth behind each, Belton 
et al (68) could only confirm that item 4 in the list above (lethargy) made a 
significant contribution to inhibit ADR reporting in the UK. Nevertheless, it was 
clear that there is significant under-reporting 
2. Spontaneous report data are collected passively relying on healthcare 
professionals and patients to recognise suspected adverse reactions, collect and 
collate relevant information and submit reports in the required format, hence the 
information received is often insufficient or incomplete. 
3. The majority of patients are lost to follow-up (FU), at least for reports submitted to 
the pharmaceutical industry. The MAH is obliged to follow-up with reporter to 
obtain clinically relevant information however around 60% of these FU attempts 
fail (62). 
4. Reporting biases exist which tend to devalue the calculation of frequencies and 
limit the use of statistical comparisons. Examples of reporting biases are: 
• Tendency to report fatal, life-threatening or serious more than non-serious (70),  
• Temporality – Weber effect suggests peak reporting in first 3-5 years of marketing 
(70), 
• Stimulated reporting – where a publication or media publicity may generate many 
further examples (71), 
• For pregnancies there is a tendency to report adverse or abnormal outcomes, thus 
there is under-reporting of full-term, normal deliveries of healthy infants (72). 
 
2.2.3 Pharmacoepidemiological studies 
Considering the limitations of pregnancy registries and spontaneous reports, regulatory 
agencies such as the EMA and FDA may mandate complimentary studies that can help 
to address these limitations. Ultimately the goal is to provide more information for better 
characterization of the risk of reproductive toxicity (73). These are usually retrospective 
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in design and are considered ‘secondary use of data’ (50) since these data were primarily 
collected for a purpose other than monitoring the safety of a specific drug such as (73): 
• Use of electronic data source (e.g. health insurance claims and electronic health 
records) 
• National registries and population-based surveillance 
• Population-based case control studies 
Evaluation of these approaches are out of scope for this PhD thesis. 
2.3 A critique of current approaches to data collection, collation and analysis 
In summary, there are many limitations in the data available for the assessment of 
pregnancy exposures and outcomes: 
• Animal models are sometimes poorly predictive of the teratogenic risk in humans. 
• Product-specific pregnancy registries can take a long time to set-up and establish 
good recruitment but often there is low enrolment and studies remain incomplete 
versus recruitment targets. This in turn means that study results are non-
informative and such programmes are costly if they yield no useful data.  
• There are no standard end-to-end processes for the capture and collation of 
spontaneous case reports of pregnancy exposures and outcomes, and methods 
of analysis vary.  
• Critical variables for generating evidence-based safety information in pregnancy 
spontaneous case reports are often missing (e.g. precise dates of exposure to 
medicines and pregnancy outcomes).  
Thus, this field is inherently difficult to study, and it suffers from a lack of systematically 
gathered data and efficient or preferably harmonised methodological approaches. 
Therefore, often there is a knowledge gap between stakeholders’ requirements for 
current, evidence-based safety information and the actual volume of relevant, timely and 
adequate information for assessing the safety of medicines use during pregnancy. 
There is a need for an efficient, sustainable and high quality system that collects, and 
supports the generation and provision of scientific and unbiased information for 
prescribers and patients.  
The overall objective of this research is to assess new and improved tools and methods 
to generate more valuable, reliable (better quality) data and thus to support a timely 
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communication of information to HCPs, pregnant women and the general public, indeed 
all stakeholders in public health. 
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3. Objectives of this Research 
• To identify drug-induced risk factors for CL/P using safety signal detection and 
safety signal evaluation techniques in safety databases such as the FDA FAERS 
system and/or the MHRA Sentinel database 
• To investigate potential big data sources such as the multiplicity of social and 
digital media webpages. This research would require the development of novel 
machine learning techniques for potential adverse drug reactions manifesting as 
adverse outcomes of pregnancy. This would be supported by human curation to 
assess the content of discussion threads concerning the use of medicines during 
pregnancy 
• To develop an enhanced pharmacovigilance method for pregnancy outcome 
monitoring using post-marketing spontaneous reports 
3.1 Safety Signal Detection and Signal Management  
Risk of Cleft Lip and/or Palate Associated With Antiepileptic Drugs: 
Postmarketing Safety Signal Detection and Evaluation of Information Presented 
to Prescribers and Patients (74) 
 
(Published in Therapeutic Innovation & Regulatory Science 2019, Vol. 53(1) 110-119 
DOI: 10.1177/2168479018761638.  – [Chapter 4 of this thesis]) 
 
Generally, health authorities have implemented pharmacovigilance databases such as 
FDA FAERS in the US (4), Eudravigilance in the EU (7), and Vigibase® in the WHO’s 
global monitoring centre in Uppsala, Sweden (75). These large relational databases 
contain millions of adverse event reports as suspected adverse reactions of medicines 
are being entered and stored. The first two named systems can be accessed publicly 
(58). Each of these systems includes a small proportion of pregnancy exposure and 
outcome reports. The primary purpose of establishing and maintaining such large 
datasets is for the detection of safety signals associated with human medicinal products.  
The Council for International Organizations of Medical Sciences (CIOMS) defined a safety 
signal as: 
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“Information that arises from one or multiple sources (including observations and 
experiments), which suggest a new potentially causal association, or a new aspect of a 
known association, between an intervention and an event or set of related events, either 
adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory 
action” (76). 
Safety signal detection and management comprises a series of related, planned 
processes and activities including (77): 
• Signal detection: Identification of safety signal via statistical algorithms  
• Signal characterisation to identify temporal association, onset time, severity, 
outcome, possible treatment, etc. 
• Medical impact assessment, according to the primary indication of the product 
(i.e. the disease under treatment, seriousness of the adverse reaction, frequency 
of occurrence of the adverse reaction, etc)  
• Signal validation: prioritization and resulting of introducing risk management plan 
and/or labeling change (78,79). Therefore, signal detection leads to hypothesis 
generation and assessment of causal association between the drug and event. 
Generally this method has proven a useful tool in facilitating the timely detection 
of adverse drug events (80–82). 
To date, only a very few studies have used spontaneous case reporting datasets to 
identify statistical signals of possible teratogenic risks of medication exposures during 
pregnancy (83,84). Hence [ in Chapter 4, (74)] we performed safety signal detection and 
evaluation to identify all antiepileptic medicines with ICSRs reported an association with 
cleft lip and/or palate in two large safety data bases; FDA FAERS in the US and the 
MHRA Sentinel database in the UK. 
Epilepsy is one of the most common chronic diseases that require continuous drug 
treatment during pregnancy. Epilepsy affects more than 1 million women of childbearing 
potential in the USA (74). Over the past two decades, several anticonvulsant drugs have 
been authorized indications beyond epilepsy, including the treatment of psychiatric 
diseases, generalized anxiety disorder, migraine prophylaxis, and management of 
neuropathic pain. In the USA, the prescription rate of AEDs has been reported at >4 
million per year for women of between 14-55 years old (74).  
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Second, we evaluated the completeness of safety information in the regulatory authority 
-approved prescribing information in the two countries. Our aim was to highlight the 
potential for optimizing maternal epilepsy management by the provision of important and 
current information on pregnancy exposures and outcomes to prescribers and patients.  
3. 2 Pharmacovigilance and Social Media 
Social Media Surveillance of Multiple Sclerosis Medications Used During 
Pregnancy and Breastfeeding: Content Analysis (85) 
 
(Published in Journal of Medical Internet Research 2019 | vol. 21 | iss. 7 | e13003 | DOI: 
10.2196/13003. [Chapter 5 of this thesis] ) 
 
In recent years, social media sources such as Twitter, Facebook and patient fora are 
providing a huge volume of information related to health, medicinal products and other 
forms of treatment (86).  
Social networks continuously increases the number of users globally (e.g., as of 11th July 
2014, Twitter has over 645,750,000 users and grows by an estimated 135,000 users 
every day, generating 9100 tweets per second) (3). 
The Pew Research Center survey has confirmed that of the 74% of adults who use the 
internet, around 80% have looked online for information about health topics such as a 
specific disease or treatment. This translates to 59% of all adults. In addition, 34% of 
internet users, or 25% of adults, have read someone else’s commentary or experience 
about health or medical issues on an online news group, website, or blog (87,88). 
Moreover, 11% of caregivers and 6% of patients share experiences and post questions 
online (3). Individual posts in social media about treatment outcomes provide early access 
to reported adverse drug reaction that could be useful due its large volume (89). 
The PV systems mainly rely on voluntary reports from consumers and HCPs, which is 
known to have the limitation of under-reporting. This shortcoming must be weighed 
against the evidence that users of social media tend to share their views openly with 
others facing similar concerns, which makes social networks unique and robust sources 
of information which is not invariably shared with HCPs and others in the chain of care. 
The ability to process large volumes of data automatically, using artificial intelligence such 
as natural language processing (NLP) and machine learning algorithms, has opened new 
opportunities for PV (3,90). 
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In this field, Web-Recognizing Adverse Drug Reactions (WEB-RADR) was a 
groundbreaking EU Innovative Medicines Innovation (IMI) project. WEB-RADR was an 
initiative to recommend policies, frameworks, tools and methodologies to use social 
media to further proactive pharmacovigilance and protection of public health (91). After 
just over three years’ research the WEB-RADR consortium recommended that social 
media channels may provide useful information related to pharmacovigilance in specific 
niche areas such as exposure during pregnancy and abuse/misuse of medicines (92). 
This project provided the stimulus for further research related to one niche area identified 
by WEB-RADR as ‘data rich’ (93). It was identified that using Twitter as the source, posts 
relating to pregnancy exposures with identifiable medicines occurred at least twelve times 
more frequently than was expected based on spontaneous sources (93) . Equally relevant 
was the fact that Twitter users could be followed for an average of 2.8 years, i.e. expectant 
mothers could be observed from first exposure to a medicinal product to term, and then 
for a period beyond, if required. The two elements suggested that further exploration of 
social media posts should be conducted to evaluate a potentially valuable source of data, 
particularly in patients with chronic diseases affecting mobility. The latter is important as 
it has been reported that the use of social media and of the internet in general is higher 
amongst patients with neurological diseases (e.g. Parkinson’s disease, multiple sclerosis) 
which limit movement (93). 
I decided to conduct further research in multiple sclerosis (MS), as it is a chronic disease 
of the central nervous system with a higher prevalence in females than males, with a ratio 
of approximately 3:1 (94,95). Female MS patients are predominantly of childbearing 
potential with the average age of disease onset being 29.2 years (94). Thus, I selected 
this patient population, as there was a significant likelihood of their being active in social 
media. Also there seemed to be a realistic prospect of the opportunity to gain insights into 
patients’ real-life experiences with medicinal products during pregnancy, as well as their 
comprehension of the benefits and risks associated with medical treatments of MS. 
 We utilized machine learning algorithms developed by WEB-RADR on pregnancy forums 
to analyze the content of posts concerning pregnancy and use of medicines for treatment 
of MS [ In Chapter 5- (85)]. We used this innovative method to engage with pregnant 
women through identifying and exploring novel sources such as social and digital media 
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to understand more about patients’ information needs, issues with medication and 
potential solutions regarding exposure to medicines during pregnancy. 
3.3 Enhanced Pharmacovigilance – PRegnancy outcome Intensive Monitoring 
(PRIM) 
An alternative to product-specific pregnancy registries? PRIM; PRegnancy 
outcomes Intensive Monitoring 
Yvonne Geissbuehler and Bita Rezaallah, Alan Moore 
Published in Journal of Reproductive Toxicology 94 (2020) 13-21 DOI: https://
doi.org/10.1016/j.reprotox.2020.03.004
 [Chapter 6 of this thesis].
Considering the document shortcomings of registries the anticipated recruitment 
of participants to registries are often not attained within the proposed timelines. 
Recruitment that is slower than forecast typifies the most common failing of pregnancy 
registries. It is important to obtain robust scientific information in a timely manner on 
missing data which may reveal potential safety concerns related to the use of drugs 
during pregnancy in the post-approval setting. In this study [Chapter 6] we 
established and described an enhanced pharmacovigilance or PRIM (PRegnancy 
outcomes Intensive Monitoring) process. The PRIM process builds on the 
knowledge from that initiated for fingolimod (Gilenya®) and was designed to 
characterize further the pregnancy outcome including risk of major congenital 
malformation in exposed infants. There are some parallels of the PRIM system to 
national and international teratology systems (e.g. UKTIS, ENITS(96)) but the PRIM 
system is, as far as I am aware unique in the pharmaceutical industry. In my view, it is 
important that high-quality data be obtained as early as possible in the post-
authorisation period in order to provide more complete information to patient 
and prescribers. 
Fingolimod is a sphingosine 1-phosphate receptor antagonist which is classified as is 
an immunomodulating agent. It was authorised for the treatment of relapsing remitting 
MS. During preclinical safety testing in rodents fingolimod was shown to cause 
teratogenic effects (persistent truncus arteriosus and ventricular septal defect) in one 
species, namely rats. Furthermore, the sphingosine 1-phosphate receptor that is 
modulated by fingolimod is known to be involved in vascular formation during 
embryogenesis, thus a potential 
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mechanistic pathway for the teratogenic effects exists. Fingolimod did not cause effects 
on sperm morphology or male fertility in animals, nor did exposure to the drug elicit any 
known genotoxic effect. The potential exposure of a female partner via seminal fluid has 
been estimated to be several thousand fold lower than the doses at which teratogenicity 
has been observed in rats (97), hence concern is very low following fingolimod treatment 
of men with MS. 
Advice and warnings are provided to prescribers at multiple points within the FDA Label 
for before initiation of fingolimod treatment, women of childbearing potential should be 
counselled regarding the potential for serious risk to the foetus and the need for effective 
contraception during treatment with fingolimod. Since it takes approximately two months 
to eliminate fingolimod from the body on stopping treatment, the potential risk to the foetus 
may persist and contraception should be continued during that period (97). 
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4. Publication I
Risk of cleft lip and/or palate associated with antiepileptic drugs: Post-marketing 
safety signal detection and evaluation of information presented to prescribers and 
patients
Bita Rezaallah, David John Lewis, Hans-Florian Zeilhofer, and Britt-Isabelle Berg.
Published in Therapeutic Innovation & Regulatory Science 2019, Vol. 53(1) 110-119 
DOI: 10.1177/2168479018761638. 
The format of this publication is adjusted to the thesis format.  
Abstract 
Background: The aim was to analyze safety data associated with the maternal use of 
antiepileptic drugs (AED) in pregnancy and to assess the risk of cleft lip and/or palate 
(CL/P) as an outcome in the neonate. A parallel objective was to assess the 
completeness of the safety information concerning pregnancy exposures in the 
Summary of Product Characteristics (SmPCs) and the Patient Information (PI) in the 
USA and the UK. Methods: We analyzed individual case safety reports (ICSRs) of CL/P 
associated with AEDs in the FDA Adverse Event Reporting System (FAERS). For the 
AEDs with signals (EB05 ≥ 2), we reviewed Drug Analysis Prints (DAPs) for CL/P cases 
in the UK MHRA. We performed descriptive analyses of relevant SmPCs and PIs in the 
UK and the USA using a checklist of recommendations collected from the literature. 
Results: In total 817 CL/P reports were identified for twelve AEDs in FAERS. Ten out of 
twelve AEDs were associated with 156 CL/P cases in the MHRA Sentinel. Safety 
information concerning pregnancy was found to be more comprehensive in UK SmPCs 
than in the US equivalents. 
Conclusions: There is statistical disproportionality in ICSRs indicative of an increased 
risk of CL/P with twelve AEDs studied. More studies are required to explore the 
association between in utero exposure to AEDs and the risk of CL/P. There are 
inconsistencies between the UK and US safety labels. CL/P associated with AEDs is an 
important topic and requires providing inclusive, unbiased, up-to-date information to 
prescribers and women of childbearing age. 
KEY WORDS — Antiepileptic drugs; cleft lip and palate; safety signal detection; labelling; 
prescribing information; patient information leaflets; pregnancy outcomes 
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Background 
Cleft lip and palate are congenital malformations that occur in the embryonic and early 
fetal stages. These malformations represent the most common congenital deformities of 
the head and neck.1 CL/P affects one in about every 700 newborns worldwide.2 Patients 
with this deformity require short-term and long-term care as well as medical, and often 
surgical, follow-up from practitioners in multiple specialties.3 The aetiology of CL/P is 
unknown but it has been hypothesized that it may be due to a combination of genetic and 
exogenous factors.3 One well-documented cause is the maternal use of certain medicinal 
products such as anticonvulsants. Causal associations have been established between 
antiepileptic drugs including valproic acid, phenytoin, phenobarbital, carbamazepine and 
topiramate and an increased risk of CL/P.4,5  
Epilepsy is one of the most common diseases that require continuous drug treatment 
during pregnancy.6 Epilepsy affects more than one million women of childbearing 
potential in the USA.6 Over the past two decades, the number of AEDs available on the 
market has increased. Several AEDs have indications for use which extend beyond 
epilepsy, including the treatment of psychiatric diseases, generalized anxiety disorder, 
migraine prophylaxis, and management of neuropathic pain.7 In the USA the prescription 
rate of AEDs has been reported at >4 million per annum for women of childbearing 
potential (14 to 55 years).8 
Pregnant women are usually excluded from clinical trials due to ethical concerns. As a 
direct result, when a medicine is authorised for marketing the safety information on the 
use of the product in human pregnancy is very limited, as the outcomes of exposures are 
very limited in number or entirely absent. Thus, safety information provided to prescribers 
and patients at the time of authorization is based at least initially, on non-clinical 
reproductive toxicology studies. It is recognized that even significant fetal malformations, 
such as those that occurred with thalidomide, do not invariably appear in all animal 
species9, nor do they always translate from animals to humans. Knowledge of the 
teratogenic potential of medicines is gained via post-marketing monitoring of accidental 
exposures to medicines at various time points during gestation. This form of surveillance 
is essential for the early detection of medication-induced fetal adverse effects.10 As a 
result, safety data related to the teratogenicity of AEDs in the literature tends to be 
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equivocal because of different methodological approaches. Generally any studies 
conducted are not sufficiently powered to provide statistically-based conclusions.4 
Consequently prescribers and patients with epilepsy face challenges when considering 
the best treatment option due to the lack of comprehensive safety information. 
In this study, our initial aim was to identify AEDs with individual case safety reports that 
were associated with CL/P in two large, post-marketing safety databases maintained by 
regulatory authorities. Secondly, we evaluated the completeness of safety information in 
approved prescribing information in two countries. Our aim was to highlight the potential 
for optimizing maternal epilepsy management by the provision of important, and wherever 
possible, current information on pregnancy exposures and outcomes to prescribers and 
patients. It is our view that the presentation of consistent, clear and current evidence to 
prescribers and patients will help to inform decisions about the management of epilepsy 
during pregnancy. Over time, we are hopeful that this will help to maintain a positive 
benefit-risk assessment by avoiding harms to the fetus. 
Methods 
We conducted this study according to the process in Figure 1. 
Selection of terms in the Medical Dictionary for Regulatory Activities (MedDRA) 
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We extracted the following preferred terms (PTs) from MedDRA version 19.0: cleft lip, 
cleft palate, cleft lip and palate.  
Safety signal detection using the FDA FAERS database 
The FAERS database includes post-marketing adverse events reported to FDA. FAERS 
receive reports from two principal sources comprising pharmaceutical companies and 
health care providers and consumers who can submit adverse event reports to the FDA’s 
MedWatch programme. 11  
Empirical evidence was produced by conducting a cumulative search in March 2016 in 
the public release version of the FAERS database11 using Empirica Signal software 
(Oracle, version 7.3, Novartis Pharma AG). A disproportionality analysis was computed 
in a data mining run using the Multi-Gamma Poisson Shrinker.11 Initially, the information 
was aggregated into a 2 x 2 table. The ratio of observed to expected counts of individual 
drug-event combinations was calculated across all of the drugs and events reported in 
the database.12 The computations produced values for the empirical Bayes geometric 
mean (EBGM) and the 90% confidence interval (CI) from 5% to 95%, EB05 and EB95, 
respectively. Extraction of data was performed using the Anatomical Therapeutic 
Chemical (ATC) level three codes for anticonvulsant drugs combined with selected PTs 
from MedDRA. Only ICSRs where the AEDs were causally suspected (S) were included 
for the period of the research (from product launch to 1Q2016). The disproportionality 
threshold of EB05≥2 was applied for this extract of ICSRs associated with AEDs. In the 
literature EB05≥ 2 is considered to be an observation of disproportional reporting (ODR)12 
and it indicates that the observed drug-event combination occurs in the dataset twice as 
frequently as expected. These values suggest a statistical association between the drug 
and event. Further investigations were conducted to determine any causal association, 
including verifying CL/P reports in the MHRA dataset and a review of the literature. 
Review of Drug Analysis Prints (DAPs) in MHRA Sentinel database 
Based on the AEDs identified with observations of disproportional reporting in the US-
based FAERS database, we conducted a manual review of DAPs to identify the number 
of CL/P reports in MHRA Sentinel.13 DAPs contain cumulative counts of all suspected 
adverse reactions reported to the MHRA via the UK Yellow Card Scheme. The MHRA 
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collects information on suspected Adverse Drug Reactions (ADR) via this scheme. The 
yellow card system was set-up in 1964 and from its inception has received reports of 
suspected ADRs directly from health care professionals and, more recently, from patients. 
Healthcare professionals have been advised to report ADRs to the Yellow Card Scheme 
even if there is only a suspicion on an association i.e. no facts or evidence is required to 
prove that a medicine may have caused the reaction. It is a statutory requirement that 
pharmaceutical companies report suspected ADRs to the MHRA, whereas reporting by 
healthcare professionals and members of the public is voluntary. It is widely recognised 
that not all ADRs are reported.13  
Data were extracted from the publicly available MHRA web resources known as Drug 
Analysis Prints14. A record was kept for each AED of the number of ICSRs for the selected 
adverse event terms, total number of reports of CL/P, and the total number of ICSRs in 
the MedDRA System Organ Class of congenital disorders. It is important to note that all 
ICSRs for each event of interest were reported only when the drug was prescribed as a 
single ingredient and not as a component of combination therapy.14 
Descriptive analysis of prescribing information 
We reviewed the literature in PubMed (from 2000 to 2016) using relevant keywords and 
phrases such as maternal epilepsy, epilepsy during pregnancy, management of women 
with epilepsy. The manufacturer’s recommendations provided concerning the maternal 
use of AEDs from literature were evaluated using an eight-item checklist to assess the 
content of the UK SmPC and US PI. 6–8,15 The results of this analysis are shown in Table 
1. A binary scoring system was adopted, based on the ‘’presence = 1’’ or ‘’absence = 0’’ 
of each item in the checklist. The percentage of the total available information was 
calculated for each approved item of labelling. Figure 3 provides the results of this 
evaluation.  
A single reviewer analysed the content of relevant sections of each reference safety 
information documents. The evaluation was inclusive of safety information provided in the 
indication, use in pregnancy, warnings and precautions, drug-drug interactions, and 
contraindications sections of the texts. In addition to the binary scoring system, specific 
information concerning the risk of CL/P was assessed in the pregnancy section of each 
reference text. The results of this assessment are presented in the discussion. The same 
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reviewer, using the same checklist, then assessed the text of each patient information 
leaflet (PIL or pack insert) for both UK and the US. No scoring was applied in to the PILs. 
Information gaps were identified and they are described in the next section.  
For the ten AEDs reference information was obtained from the USA prescribing 
information and patient information leaflet (PIL) were obtained from the Drugs@FDA 
database.16 The UK was used as a reference source for the European Union because 
English is the common language with the US, thus obviating any requirement for 
translation. Approved SmPCs and PILs were extracted from the UK electronic Medicines 
Compendium (eMC).17 Information on both of these websites is regularly updated, and 
the eMC provides the full document history with changes recorded by date. We reviewed 
the most recent label in both websites for each product irrespective of the manufacturer. 
The last search for this information was performed in March 2016. This article does not 
contain any studies with human or animal subjects performed by any of the authors. 
Table 1. Management of epilepsy during pregnancy 
Precautionary approaches for the use of AEDs in epileptic women of childbearing potential 
Dose adjustment especially before gestation and later on during pregnancy with lowest effective dosage 
for effective seizure control.8,15 
Serum drug concentration monitoring during entire pregnancy. Plasma concentrations of AEDs tend to 
decrease from the first to the third quarter of pregnancy.8,15 
Use of effective contraceptives for women of childbearing potential because of drug-drug interactions 
with AEDs and hormonal contraceptives. 8,15 
Because of the risk of folate antagonism with certain AEDs, prescribing folic acid prior to and during 
pregnancy is suggested in order to avoid major congenital malformation in the fetus (e.g. neural tube 
defects)8,15 
Administration of vitamin K1 to the newborn and to mother during delivery helps to avoid bleeding 
disorders8,15 
Polytherapy should be avoided, as far as is possible in pregnant females. If polytherapy is required the 
teratogenic risk depends on the combination of medicines that is prescribed. Several studies have 
suggested avoiding polytherapy with valproic acid in particular to reduce the risk of MCM 7,8,15.  
Equally it is important that prescribers consult patients to ensure pregnancy is planned in order to 
minimize the risks8. 
 It is also considered good practice to avoid the sudden discontinuation of anticonvulsant therapy in case 
of pregnancy8. 
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Results 
Disproportionality analysis scores from FAERS 
The results of the disproportionality analyses are presented in Figure 2 alongside the 
counts of ICSRs. Twelve AEDs were statistically associated with the occurrence of CL/P 
in this database. Topiramate followed by phenobarbital, primidone, lamotrigine and 
carbamazepine had higher EBGM values than valproic acid, which has a well-
documented association with causing congenital anomalies. Whilst mephenytoin had the 
highest EBGM score of 49.7 (90% CI, EB05-EB95; 4.4 – 137.2) this was for only four 
ICSRs. It is recognised that the disproportionality statistic tends to be unreliable when 
calculated for low numbers of reports.18 In contrast there were three medicinal products, 
namely topiramate, lamotrigine and valproic acid were associated with >100 ICSRs and 
a relatively high EBGM (>6). 
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Drug Analysis Prints for AEDs from MHRA 
Ten of the twelve AEDs identified in FAERS were reported in the MHRA DAPs with 156 
case reports of drug-associated CL/P. There were no ICSRs including CL/P for 
oxcarbazepine and mephenytoin in Sentinel. Mephenytoin was excluded from further 
research because there were no reports of CL/P recorded in Sentinel and the because of 
the limitation previously described for the disproportionality statistic generated from 
FAERS.  
Valproate, phenytoin, phenobarbital and primidone had the highest number of ICSRs 
describing CL/P. We recorded the total number of ICSRs in the Congenital Disorders 
System Organ Class in MedDRA to show the overall teratogenic profile of each drug; 
valproic acid followed by carbamazepine and lamotrigine has the highest number of 
reports of congenital anomalies. Table 2 shows CL/P reports on Sentinel. 
Table 2. The number of case reports for cleft lip and/or palate associated with antiepileptic 
medicines reported to the MHRA in the UK 
Suspected 
Drug 
Congenital 
Disorder 
System 
Organ Class 
Cleft Lip 
Reports 
Cleft 
Palate 
Reports 
Cleft Lip 
and Palate 
Reports 
Total Number 
of cleft lip 
and/or palate 
Reports 
Valproic acid 920 3 32 1 38 
Carbamazepine 263 3 10 0 13 
Lamotrigine 181 0 2 2 4 
Phenytoin 128 13 19 0 32 
Topiramate 121 1 2 4 7 
Levetiracetam 76 0 0 1 1 
Primidone 74 6 21 0 27 
Phenobarbital 58 11 17 1 29 
Gabapentin 27 2 2 0 4 
Clonazepam 19 0 1 0 1 
 
 
Evaluation of prescribing information for AEDs  
Figure 3 shows summary of the completeness of the information presented within the 
prescribing information between UK and the US. 
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Phenobarbital was excluded from further analysis because there was no PI in the 
Drug@FDA website at the time of this research. 
In general, the UK SmPCs that were evaluated included more information on safety in 
pregnancy than the US prescribing information. Notably the safety information content for 
valproate was more inclusive in the UK19 than in the US.20 It is unclear why for 
carbamazepine, which has a well-documented safety profile, the information appears to 
be incomplete in the US PI.21,22 The FDA has begun to address the potential gaps in 
labelling by the introduction of the ANDA guidance which obliges generic manufacturers 
to align labelling for new generics with the approved label for the reference listed drug 
(RLD).23 As recently as July 2016 the FDA provided further guidance to applicants, in 
order to extend the recommendations to include scenarios where the RLD has been 
withdrawn.24 In the light of the guidance provided by the European Commission 25on the 
content of SmPCs it is also difficult to comprehend the gaps in the information content of 
the UK SmPC for clonazepam.26,27  
The risk of CL/P is described in the approved labelling for valproate, topiramate, 
carbamazepine and phenytoin in both the UK and the USA19–22, 28–31. Broadly, the 
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statements reviewed were consistent with literature.4,5 However, there were some notable 
differences in the recommendations provided in the UK and US for certain products. 
Illustrative examples of these discrepancies are provided below. 
Topiramate 
The UK SmPC30  includes a statement which reads: ‘’Contraindicated in pregnancy and 
in women of childbearing potential if a highly effective method of contraception is not used 
for use in migraine prophylaxis.’’ In the US this guidance was not present in the 
prescribing information despite migraine being an approved indication.31  
Phenytoin 
The US PIL for phenytoin28 includes a warning concerning the management of epilepsy 
in pregnancy: ‘’… If you take [phenytoin] during pregnancy, your baby is at risk for serious 
birth defects...’’ and ‘’…. If you take [phenytoin] during pregnancy, your baby is also at 
risk for bleeding problems right after birth...’’28. This information is not present on the UK 
PIL for phenytoin.  
Carbamazepine 
Studies have shown that in utero exposure to AEDs, especially polytherapy including 
valproate increases the risk of congenital malformation up to three-fold.8 The SmPC for 
carbamazepine in the UK 21 advises that ‘’ …the risk of MCM to [carbamazepine] as poly-
therapy may be higher in poly-therapy combinations that include valproate’’. A second 
recommendation states: ‘’…In order to prevent bleeding disorders in the offspring, it has 
also been recommended that vitamin K1, be given to the mother during the last weeks of 
pregnancy as well as to the neonate.’’ Neither of these two important recommendations 
are present in the US PI.22  
Primidone 
According to the literature, primidone is teratogenic 5 and maternal exposure to primidone 
is associated with an increased risk of cleft palate and congenital heart diseases.32 There 
is evidence that maternal exposure to primidone may increase the risk of major congenital 
malformations, and the product can delay the development of the fetus. 5,32 Again, there 
are essential differences between the UK and US labelling. On the primidone UK label33 
it is stated that “…[primidone] is suspected to have caused serious birth defects, 
congenital abnormalities including cleft palate…’’ and also “…treatment with folic acid 
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although controversial, should be considered.’’. But on the primidone US label34 only the 
class risk of ADEs after exposure is specified following this statement ‘’…The effects of 
[primidone] in human pregnancy and nursing infants are unknown.’’. Again with primidone 
the UK PIL35 recommends that women with epilepsy should use an effective contraceptive 
method, due increased risks to the fetus and reduced folic acid levels in maternal blood. 
In contrast a US PIL for primidone34 did not provide any of the information for patients as 
specified immediately above. 
Information about the impact of AEDs on hormonal contraception, use of effective 
contraceptive methods, and the importance of planning pregnancy is not always provided 
to patients, despite the impact of pregnancy on epilepsy and seizure control and the 
potential teratogenic effects of AEDs on the fetus.36 According to the literature 
approximately 75% women with epilepsy of childbearing age were prescribed a category 
D or X (according to FDA’s Pregnancy and Lactation Labelling Rule) AED and were not 
on contraception, despite the risk of having a baby with a congenital anomaly.36 
Additionally, among the 26% of this population prescribed a contraceptive, 53% were 
using a product with potential drug-drug interaction with AEDs, which could of course 
reduce the efficacy of the contraceptive.36  
Lamotrigine 
According to the literature, lamotrigine is associated with drug-drug interactions with 
estrogen-containing oral contraceptives.37 Lamotrigine also has folate antagonist 
properties which, it has been hypothesized, may induce major malformations in the fetus 
after in utero exposure.38 It was determined that the safety information about exposure to 
lamotrigine during pregnancy differs between the US and the UK. The US-approved label 
includes the statement ‘’...there are no adequate and well-controlled studies in pregnant 
women...’’.39 In contrast, the text within the lamotrigine UK SmPC 40 includes detailed 
information: ‘’…. A large amount of data on pregnant women exposed to [lamotrigine] 
monotherapy during the first trimester of pregnancy (more than 8700) do not suggest a 
substantial increase in the risk for major congenital malformations, including oral clefts’’ 
In addition there is a recommendation for pregnant women to supplement their normal 
intake of folic acid. In the UK PIL for lamotrigine41 there is reference to a potential risk of 
birth defects, including CL/P when used in the first trimester. Information is provided 
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concerning the impact of pregnancy on the effectiveness of lamotrigine, and there is a 
recommendation concerning the intake of extra folic acid before and during pregnancy. 
On the US equivalent 39 these recommendations are not present and the following text is 
present: “It is not known if [lamotrigine] will harm your unborn baby.’’ 
Findings in the literature for human maternal exposure to lamotrigine monotherapy and 
the risk of MCM and CL/P vary between different pregnancy registries.42 In 2012, a 
systematic review of the major pharmacoepidemiological studies, including registries. 
was performed.42 The range of risk of major malformations in general following in utero 
exposure to lamotrigine was from 2.0% to 5.6% and the risk of CL/P ranged from 0.1% to 
0.4%.37,38,42–46 New data from the UK and Ireland epilepsy and pregnancy registry were 
released in 2014.43 Analyses of these data revealed that among 2,089 first trimester 
exposures to lamotrigine monotherapy there were 49 instances of MCM, with 2 (0.1%) 
reports of CL/P.43 
Levetiracetam 
Results of the non-clinical studies for levetiracetam are consistent with the safety 
information presented from the animal studies that are reported in the US and UK labelling 
including “…increased incidences of minor fetal skeletal abnormalities’’.47,48 However, 
planning pregnancy is recommended in the UK SmPC48, as well as avoidance of poly-
therapy and avoiding sudden discontinuation of the drug. None of these three pieces of 
information are present in the US PI.47 A systematic review of the safety of levetiracetam 
in pregnancy revealed a MCM rate of 2.2%.49 Among 1,213 monotherapy exposures to 
levetiracetam from different pregnancy registries, twenty-seven outcomes with MCM 
were reported (95% CI of 1.53-3.22) with a single case of CL/P.  
There are a very few human studies of the safety of levetiracetam during pregnancy. 
Consequently our view is that the safety warnings about the maternal use of levetiracetam 
in both the UK and FDA labels are incomplete for both prescribers and patients.47,48,50  
Gabapentin 
In the UK SmPC51 it is recommended to use and effective method of contraception, to 
avoid polytherapy, to plan pregnancy and to avoid the sudden discontinuation of the drug. 
In contrast these recommendations do not appear in the US PI.51,52 A systematic review 
of the safety of gabapentin in pregnancy revealed a rate of 1.7% MCM (five ICSRs) with 
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no reports of CL/P among 294 congenital anomalies.53 The sample size of these studies 
was insufficient to draw firm conclusions about teratogenic effects and specifically 
concerning the risk of CL/P.53–55 Despite the evident gaps in the data the UK PIL for 
gabapentin 56 included a reference to planning pregnancy and recommended the use of 
an effective contraceptive method as the risk to the fetus was unknown. This information 
was not present in the US PIL.52 
Oxcarbazepine 
A systemic literature review of the safety of oxcarbazepine in pregnancy reported a rate 
of 2.0 % MCM (eight case reports) among 414 exposed fetuses.57 The same study 
revealed a 3.3% rate of congenital anomaly from the European registry of antiepileptic 
drugs and pregnancy. According to this study the prevalence of congenital anomaly 
including CL/P was not higher than background rate.57 The information is accurately 
reflected in both the UK and US labels.58,59  
 In the UK SmPC for oxcarbazepine recommendations for management of a maternal 
epilepsy include recommendations for drug dose adjustments, monotherapy, use of folic 
acid prophylaxis during the pregnancy, avoidance of sudden discontinuation of the drug 
and the risk of bleeding disorder for mother and neonate during delivery and the use of 
prophylactic vitamin K1.58 These six pieces of information or specific recommendations 
are not provided in the US PI.59 
Clonazepam 
Clonazepam is a benzodiazepine which is indicated for treatment of epilepsy, panic 
attacks and anxiety.60 There are of course substantial published data related to the 
teratogenic effects of benzodiazepine in general and increase risk of MCM including 
CL/P.61 However limited data was available in literature about specific risk of CL/P and 
clonazepam.60  
The US PI27 for clonazepam includes the statement that: ‘’…a similar pattern of 
malformations (cleft palate, open eyelid, fused sternebrae and limb defects) was 
observed in a low, non-dose-related incidence in exposed litters from all dosage 
groups...‘’. This document also recommends: ‘’….Because use of these drugs is rarely a 
matter of urgency in the treatment of panic disorder, their use during the first trimester 
should almost always be avoided. ‘’ In addition, general recommendations and concerns 
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about the use of AEDs is present. Panic disorder is not an approved indication for 
clonazepam in the UK.26 Compelling data about the risk of CL/P were published in 2005.62  
Valproate 
In February 2016 there was a publication informing stakeholders about the high 
teratogenic potential of valproate, with the implementation of additional risk minimisation 
methods and a requirement for the communication of this information.63 The MHRA 
introduced four types of resources to communicate the safety risk to women of 
childbearing potential, including a booklet for health care professionals, a consultation 
checklist, as well as a medication guide, and a card to be given to patients. This, in our 
view, constitutes an optimization of the risk minimization measures for the prescriber and 
patient. We consider it essential to provide this information and advice prior to conception, 
ideally with follow-up via postpartum education. The introduction of these measures 
followed the initiation of a referral procedure across the European Union (according to 
Article 31 of Directive 2001/83/EC). This led to the full evaluation of safety data related to 
pregnancy exposures, and a regulatory decision to strengthen warnings on the use of 
valproate-containing medicines in women and girls.64 The safety review was first initiated 
by French national competent authority, ANSM (Agence Nationale de Sécurité du 
Médicament et des Produits de Santé or French Agency for the Safety of Health 
Products), following an analysis of malformations linked to the drug.65 The European 
Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) 
plans to hold its first public hearing to discuss the safety of the use of valproate during 
pregnancy commencing on 26 September 2017.66 Patients residing in the European 
Union have been invited to speak about their experiences with valproate during this 
PRAC-initiated public safety review. The hearing is part of a broader plan to determine 
the adequacy of current warnings, precautions, and prescribing restrictions concerning 
adverse outcomes in babies born to women who take valproate during pregnancy.65 
Discussion  
In this research, we set out to identify all AEDs that were statistically associated with the 
risk of CL/P in the MHRA UK Sentinel and US FAERS post-marketing adverse event 
reporting databases. Relatively high numbers of CL/P safety case reports were present 
in both databases for valproic acid, phenytoin, phenobarbital, primidone, carbamazepine, 
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topiramate and lamotrigine. We also conducted a descriptive study based on a structured 
qualitative assessment of the product labelling in the UK and US. This was performed to 
understand the completeness and currency of the information provided. Even where data 
are available concerning real world use, such as from spontaneous reports, disease or 
drug registries, and pharmacoepidemiological studies there are still inconsistencies in the 
information provided via the approved prescribing information. Further to this, it is notable 
that there are important differences in the information content presented prescribers in 
the UK and US.  
The safety profile of human medicinal products during gestation can only be evaluated in 
the post-marketing period due to practical and ethical limitations in the development 
phase. Effective post-marketing surveillance systems are essential to enable the capture, 
collation and evaluation of information on pregnancy exposures and outcomes. There is 
need to improve the communication of the safety profiles of medicines used in pregnancy. 
A potential solution to enhance the existing system would be to encourage prescribers 
and patients to report exposures to a central authority via transfer of electronic health 
records, with appropriate data security measures. By centralizing the repository for these 
data, followed by expert scientific evaluation, detailed and consistent information about 
the exposures and outcomes of human medicines taken during pregnancy could be 
provided to stakeholders.  
Although it is recognized that there are existing disease registries for epilepsy, and 
pregnancy registries for AEDs, there is still a need to improve the structure and conduct 
of post-marketing surveillance in this domain. Ideally, centers for data collection and 
collation should work in tandem. It would be possible to broaden existing networks to 
improve and extend the evidence base for the provision of information about pregnancy 
exposures and outcomes. This would take time, effort and careful planning to optimize 
the effort and harmonize data collection. 
Conclusion  
Improving the communication of safety information to stakeholders should be considered 
by sharing verified data, by constructing globally consistent, clear and appropriate 
recommendations in a timely, transparent, unbiased and evidence-based manner. 
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Limitations  
The primary limitation of spontaneous reporting schemes such as the UK Yellow Card 
system and the FDA MedWatch scheme is the significant level of under-reporting. ADR 
reporting rates may be influenced by the seriousness of reactions, by the ease of 
recognition of the ADR, by the extent of use of a particular drug, and by the level of 
publicity about the medicinal product. Spontaneous reporting systems cannot be used to 
determine incidence of a particular ADR as denominator data are not available and 
causality cannot always be established.  
During our literature review we concluded that pregnancy registries usually report the 
overall risk of congenital anomalies rather than a specific type of malformation such as 
CL/P therefore we discussed congenital malformations in general to described the 
teratogenic potential of a particular drug. Another limitation of reviewing data from 
different registries is the heterogeneity of their designs and the variety of patient 
populations included, which makes it difficult to draw firm scientific conclusions.  
The relevant regulatory authorities approved all of the prescribing information available 
to us, therefore we did not assess the compliance of the information content. However, 
we did assess the completeness of the safety information provided in the approved 
prescribing information and pack inserts against the evidence in the literature.  
Because the FDA’s Pregnancy and Lactation Labelling Rule (PLLR) applies only in the 
US, we did not consider the assigned PLLR categories in this study; only the content of 
the text was evaluated.  
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Abstract 
Background: Multiple Sclerosis (MS) is a chronic neurological disease occurring mostly 
in women of childbearing age. Pregnant women with MS are usually excluded from 
clinical trials; as users of the Internet, however, they are actively engaged in threads and 
forums on social media. Social media provides the potential to explore real-world patient 
experiences and concerns about the use of medicinal products during pregnancy and 
breastfeeding. 
Objective: To analyze the content of posts concerning pregnancy and use of medicines 
in online forums; thus, to gain a thorough understanding of patients’ experiences with MS 
medication. 
Methods: Using the names of medicinal products as search terms we collected posts 
from twenty-one publicly available pregnancy forums, which were accessed, between 
March 2015 and March 2018. After the identification of relevant posts, we analyzed the 
content of each post using a content analysis technique, and categorized the main topics 
that users discussed most frequently. 
Results: We identified six main topics in seventy social media posts. These topics were: 
(1) Expressing personal experiences with MS medication use during the reproductive 
period (55 out of 70, 80%); (2) Seeking and sharing advice about the use of medicines 
(52 out 70, 74.28%); (3) Progression of MS during and after pregnancy (35 out of 70, 
50%); (4) Discussing concerns about MS medications during the reproductive period (35 
out of 70, 50%); (5) Querying the possibility of breastfeeding while taking MS medications
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(30 out of 70, 42.85%); (6) Commenting on communications with physician(s) (26 out of 
70, 37.14%). 
Conclusions: Overall, many pregnant women or women considering pregnancy shared 
profound uncertainties and specific concerns about taking medicines during the 
reproductive period. There is a significant need to provide advice and guidance to MS 
patients concerning the use of medicines in pregnancy and postpartum, as well as during 
breastfeeding. Advice must be tailored to the circumstances of each patient and, of 
course, to the individual medicine. Information must be provided by a trusted source with 
relevant expertise, and made publicly available. 
Key words: Social media vigilance, multiple sclerosis medications, pregnancy, 
postpartum, breastfeeding, text mining 
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Introduction 
Multiple Sclerosis (MS) is a chronic disease of the central nervous system [1]. It is more 
prevalent in females than males, with a ratio of approximately 3 to 1 [2]. Female MS 
patients are predominantly of childbearing potential with the average age of disease onset 
being 29.2 years [1]. The prevalence of MS is more common further from the Equator, 
this can be explained due to vitamin D deficiency rather than only genetics.[3] Pregnancy 
is not contraindicated in MS but remains a concern among female patients for a variety 
of reasons [2]. Pregnancy appears to have a protective effect in MS such that pregnant 
women suffer a reduced number of MS relapses, especially during the third trimester 
(reduction of around 70%). Thereafter, relapse rates tend to increase in the first three 
months postpartum [4,5]. However, this protective effect of pregnancy and the risk of 
postpartum relapse are both related to each patient’s MS history and current disease 
activity [6].  
Pregnant women are usually excluded from clinical trials due to ethical issues [7]; thus, 
safety information about human drug exposure during pregnancy is very limited at the 
time a marketing authorization is granted [8]. Pregnancy registries have been developed 
to address this gap in the safety profile of newly authorized medicines. Despite the evident 
advantages, such registries often suffer from low enrolment, resulting in delayed findings, 
selection bias, heterogeneity in data collection methods, and high costs [9]. As a result 
prescribing information and patient information leaflets, contain limited safety information 
for pregnant and breastfeeding patients [8]. Despite the evident need, to the best of our 
knowledge there are no globally accepted guidelines by regulatory agencies for the 
medical management of MS during pregnancy and breastfeeding. 
The rapid expansion of the Internet and the availability of various social media platforms 
in recent years has increased the frequency with which patients use the Internet [10]. In 
the US, 90% of adults use the Internet regularly, and 72% have searched for health 
information online [11]. Pregnant women in particular often access the Internet to seek 
health information [12]. A cohort of pregnant women has been identified in Twitter using 
text mining and machine learning [13]. The availability of data for this cohort of pregnant 
women in social media provides an opportunity to explore and gain further insights into 
patient experiences related to MS medications. Therefore, by increasing HCPs’ 
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awareness of patient concerns, carers can better advise patients during clinical visits. The 
objective of this study was to analyze data qualitatively and describe the content of posts 
in online pregnancy forums in order to understand better patient experiences resulting 
from the use of MS medications during pregnancy, postpartum and breastfeeding. 
Methods 
Data Acquisition and Classification 
We obtained data from publicly available online pregnancy forums. An existing digital 
monitoring platform called MedWatcher Social was utilized; this system has been 
described elsewhere [10,13,14]. MedWatcher Social comprises the natural language 
processing component that acquires public data from the Internet, apply classification 
algorithms, and extract adverse event-related posts. The aggregated frequency of 
product-event pairs identified by MedWatcher was concordant with data from the public 
FDA Adverse Event Reporting System by System Organ Class (SOC) [9]. 
The classifier was designed to automatically collect, classify, and analyze social media 
discussions and threads pertaining to medical products [10,13,14]. The system collected 
online forum posts both retrospectively and prospectively, via authorized third-party data 
vendors, using the names of medicinal products as search terms. After data ingestion, a 
naïve Bayes classifier scored and filtered each post according to its relevance. Using 
statistical machine learning and a training set of over 360,000 hand-labeled social media 
posts, the classifier was trained to recognize: 
• Descriptions of adverse drug reactions,  
• Medication errors,  
• Product quality issues, and  
• Other patient experiences with medical products 
The classifier was also used to exclude ‘noise’ (e.g., non-valid product posts and spam). 
After filtering the data, natural language processors were applied to recognize and extract 
product and symptom terms through tokenization and proprietary taxonomies. 
References to products were standardized and consolidated, and vernacular descriptions 
of medical concepts were translated into the best matched term within the Medical 
Dictionary for Regulatory Activities (MedDRA) terminology [15]. For this analysis, we 
identified and extracted a dataset from the system comprising posts acquired from twenty-
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one publicly accessible pregnancy social media forums listed in Table 1, published 
between March 2015 and March 2018. The forum data were acquired using third-party 
data from vendors (Socialgist and Datasift) and thus was dependent on availability from 
those vendors. Data were not randomly sampled; rather, we selected any forums that 
were both available from Socialgist or Datasift and were dedicated to discussions around 
pregnancy or breastfeeding. The classifier used for the analysis was trained only on 
English language data, so we only used English language posts for this analysis. 
Additionally we identified a list of products authorized for the treatment of MS, and filtered 
the data accordingly. The products were alemtuzumab, teriflunomide, interferon beta-1a, 
interferon beta-1b, glatiramer acetate, daclizumab, dimethyl fumarate, fingolimod, and 
natalizumab. Posts mentioning either the active substance or brand name of each 
medicinal product were collected as shown in Multimedia Appendix 1. 
Table 1. Lists of publicly available pregnancy forums 
List of pregnancy online forums 
Babiesbase.com 
Babycenter.com 
Babycenter.com.au 
Babycentre.co.uk 
Cafemom.com 
Dcurbanmom.com 
Fertility.org 
Magrossesse.com 
Mumsnet.com 
Whattoexpect.com 
Swissmomforum.ch 
Baby-cafe.cz 
Babycenter.ca 
Babycenter.in 
Circleofmoms.com 
Essentialbaby.com.au 
Justmommies.com 
Netmums.com 
Thebump.com 
Fertilethoughts.com 
67 
 
Scarymommy.com 
 
Content Analysis 
After automated classification, reports were manually divided into two groups: discussions 
related to pregnancy or breastfeeding, and posts containing no thread relevant to 
pregnancy or lactation. In this study, we focused only on posts where an individual wrote 
about an experience related to a current or previous pregnancy, or breastfeeding related 
to medicinal treatment of MS medication, or a complication of MS or treatment of this 
disease. 
A human expert reviewed the posts to characterize the experiences described in each 
post. First, we collected any medical information that a user shared in a post, such as 
time since their diagnosis of MS, planned or unplanned pregnancy, gestational age, 
outcome of pregnancy (or multiple pregnancies), number of pregnancies, current or 
previous pregnancy, concomitant medication(s), and John Cunningham (JC) virus 
serology results. Second, for the questions and/or concerns written in posts, we applied 
the content analysis method [16,17]. The aim was to use this categorization to identify 
common themes (threads) and to assess their frequency. To start with, we used open 
coding for obtaining the sense of the content. The coding team was composed of a 
physician (BR), a pharmacovigilance expert (DL), a statistician (AZ) and a machine-
learning expert (CP). We created a codebook based on features that individual users 
shared (e.g. what were their concerns and what action was taken with the medication(s), 
etc.). Subsequently the initial codes formed higher order headings of main topics. The 
entire data set was reviewed and posts were assigned to each topic. In addition, we 
quantified the content by measuring the frequency of each topic, which we cautiously 
proposed may stand as a proxy for significance [17]. 
The unit of analysis was the number of posts. It should be noted that in each individual 
post, the author might have provided comments on more than one main topic. 
Ethic Statement 
All human subject data used in this analysis were publicly available and have been 
presented in a de-identified format; in no case was any personally identifiable information 
(PII) reviewed. In fact, the classifier was set-up to de-identify individual posts by removing 
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any text relating to PII. We did not contact any individual on social media for follow-up as 
felt that this posed unacceptable ethical and potential data privacy concerns. Thus, all of 
the posts were evaluated without knowledge of the identity of the patients involved.  
Results 
Data Processing Results 
Our initial dataset comprised 376,691 posts that had been shared publicly on the 
pregnancy forums during the four-year period of observation. This dataset was reduced 
to 168 (0.04% of total) posts relevant to pregnancy or breastfeeding and MS after filtering 
for posts mentioning the specified products. Finally, 16 posts containing spam-like 
language, non-English text, or non-valid mentions of the product were automatically 
identified as irrelevant and were filtered out, leaving 152 posts for analysis as shown in 
Table 2. 
Table 2. Result of data processing 
Number of posts extract from 
database via automation 
Pre-Spam Removal Post-Spam Removal 
Posts mentioning any product 376,691 359,306 
Posts mentioning multiple 
sclerosis products 
168 152 
Manual selection of unique 
posts where previous or current 
pregnancy was mentioned 
152 70 
Among the 152 posts, 70 unique posts discussed a current or previous pregnancy or 
breastfeeding experiences related to MS medications. The remaining 82 posts were non-
informative concerning pregnancy or breastfeeding. As a result, we focused on the 70 
posts that provided pertinent and substantive information. Table 3 provides illustrative 
examples of medically relevant information shared by the post authors. We could not 
identify the gender of individual users in each post, but based on the content, and the way 
that the text related personal sentiments and explanations, we assumed that it was 
predominantly pregnant women who authored the content. 
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Table 3. Medically relevant information shared by MS patients on the online post 
Information shared in posts Number of posts (%) 
N=70 
Illustrative text extracted from post 
Gestational age 
First trimestera 
Second trimester 
Third trimester 
22 (31.42%) 
8 (11.42%) 
7 (10%) 
7 (10%) 
‘’I am 30 weeks pregnant’’ 
Time diagnosed for MS 21 (30.00%) ‘’I got diagnosed in 2009’…’ 
Unplanned pregnancy 22 (31.42%) 
‘’…found out I was pregnant at 8 weeks and 
immediately stopped Gilenya…’’ 
Planned Pregnancy 8 (11.42%) 
‘’…stopped the medication in July to get 
pregnant…’’ 
Outcome in Newborns 18 (25.71%) ‘’My daughter is [a] healthy one year old…’’ 
Previous pregnancy 10 (14.28%) ‘’It’s my second baby…’’ 
First pregnancy 7 (10.00%) ‘’It’s my first pregnancy…’’ 
Concomitant medication 5 (7.14%) 
…‘’Taking Methadone and Percoce as 
well’…’ 
JC virus result 3 (4.28%) ‘’…I am JC positive…’’ 
A first trimester (1-12 weeks), second trimester (13-28 weeks), third trimester (29-40 weeks) according definition available in the US 
Department of Health and Human Services at https://www.womenshealth.gov/pregnancy/youre-pregnant-now-what/stages-
pregnancy 
Patients indicated that their newborn children were healthy, with no reports of congenital 
anomalies, in 18 of 70 posts (25.71%). MS patients shared in 22 (31.42%) posts their 
gestational age, and in 21 (30%) posts the year of the first diagnosis of MS were 
mentioned. 
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Content Analysis Results 
Upon detailed review of the content of each post, we identified six main topics, which are 
presented in Tables 4 and 5. Patients used the pregnancy forums as an outlet for: 
(1) Describing in detail personal experiences with medicines, including changes in 
therapy, stopping medication, taking medication during pregnancy and breastfeeding;  
(2) Sharing and seeking information about MS medication in pregnancy and postpartum;  
(3) Reporting MS progression (disease status) in this period;  
(4) Expressing uncertainty or fears related to MS medication;  
(5) Discussing or commenting on breastfeeding and MS medication; 
(6) Sharing details or comments on communications with HCPs involved in the care of 
the pregnant mother or offspring. 
 
Table 4. Main topics posted by individuals on social media related to MS, 
pregnancy and breastfeeding 
Topic N b (%) 
1. Discussion about personal experiences with MS medication in 
reproductive period 
56 (80%) 
Switched, switching, or will change medication during pregnancy or breastfeeding 28 (40%) 
Stopped, stopping, or will stop medication during pregnancy or breastfeeding  26 (37.14%) 
Took, taking, or will take medication during pregnancy or breastfeeding 22 (31.42%) 
2. Reporting MS Diseases Status during and after pregnancy 35 (50%) 
Reported no relapse and healthy pregnancy 16 (22.85%) 
Reported relapse during pregnancy 15 (21.42%) 
Reported relapse postpartum 12 (17.14%) 
3. Seeking and Giving advice 52 (74.28%) 
Seeking advice about MS, pregnancy and postpartum 36 (51.42%) 
Giving advice about MS, pregnancy and postpartum 16 (22.85%) 
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4. Communication with the HCP 26 (37.14%) 
Good communication and patient express trust in the HCP 8 (11.42%) 
Poor communication 18 (25.71%) 
5. Discussion related to breastfeeding and MS medication 30 (42.85%) 
6. Express uncertainty and fear about MS medication in reproductive period 35 (50%) 
b Percentages are calculated using N=70 total individual posts about pregnancy and breastfeeding. The 
unit used was topic posted. One post may contain several pieces of information or an individual might have 
written about more than one pregnancy experiences. 
Table 5. Illustrative example of posts related to each main topic and subtopic 
Topic Subtopic Illustrative text extracted from individual posts 
Sharing experiences on MS 
medications  
Stopping medication ‘’…I don't plan on taking anything [during] this pregnancy 
either.’’ 
 Switching treatment ‘’...I took Copaxone throughout my pregnancy and 
breastfeeding and then started Tecfidera...’’ 
 Taking medication ‘’...I took Copaxone throughout my pregnancy and 
breastfeeding under the direction of my neuro [sic]....’’ 
MS Diseases Status No relapse ‘’...I had no issues with my MS during my pregnancy...’’ 
 Relapse in pregnancy ‘’...I have very active MS had 2 relapse in 29 weeks journey. 
Have been on copaxone [sic] throughout and short steroids 
course twice...’’ 
 Postpartum relapse ‘’...I didn't start flaring up until my son was over 6 months old. 
I've been in [sic] Tysabri since...!’’ 
Seeking and Giving advice Seeking advice ‘’...I am 8 weeks pregnant and was taking my gilenya [sic] 
during those 8 weeks meaning the baby will be exposed to it 
for 2 additional months Has anyone dealt with a pregnancy 
like this? The doctors have such limited information.’’ 
 Giving advice ‘’...MS patients are advicesd [sic] to come off their meds 
when trying for a baby. my understanding is that Copaxone 
and the interferons are perfectly ok to take until a positive 
pregnancy test. I'm a little bitter because I got the same 
advice and suffered a disabling relapse as a result. 
Copaxone especially is probably fine to take even during 
pregnancy (though now that I have finally found luck, I have 
chosen to stay off during pregnancy and restart after birth 
and yes I will be breastfeeding). Good luck.’’ 
Breastfeeding   ‘’...My neuro [sic] recommended a 3-day steroid infusion 
treatment. I had to pump and dump [sic] the whole time and 
for 24 hours following the last infusion…’’ 
Express uncertainty or 
concern(s) 
 ‘’...I just found out I am unexpectedly pregnant and conceived 
while in gilenya [sic]. Everything everyone has been telling 
us has made us to start thinking about terminating the 
pregnancy, which I really badly do not want to do. But if this 
child is any kind of danger I don't want to risk that. I just want 
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someone to tell me it will be okay. I just don't know if that's 
realistic...’’ 
Communication with HCPs Good communication ‘’...I have been on Tysabri! I talked to neuro [sic] and she 
completely calmed my nerves! She just had me stop all meds 
for now then we'll switch to Copaxone after birth...’’ 
 Bad communication ‘’...My neurologist never mentioned anything, and said I can 
just start taking Gilenya after I give birth. She said attacks 
are more common after birth but didn't suggest anything to 
prevent them...’’ 
 
Discussion 
In this study, we performed text mining and characterization of posts acquired from 
pregnancy-related online forums where patients discussed MS medications. The aim of 
this study was to gain a better understanding of information sought by, or provided to, 
pregnant and breastfeeding MS patients who are active on social media. Our data shows 
that the main topics of concern were switching, stopping or taking medication during and 
after pregnancy; there was clear evidence of information seeking related to the risk of MS 
relapse during pregnancy or postpartum; and finally, questions were raised about 
breastfeeding while on medication. The most frequently observed content (approximately 
80% of all relevant posts) was personal experiences with MS medications. Individuals 
shared their reasons for personal decisions regarding treatment, described how they felt 
after changes in therapy: switched, started, or stopped medication, whether this was due 
to a HCP’s recommendation or due to the patient’s personal beliefs. 
Patients used online forums to seek information from, and provide advice to, others (the 
latter occurred in 52 out of 70 (74.28%) of posts). In 36 (51.42%) posts individuals asked 
their peers about decisions and outcomes: or about experiences when taking a specific 
medication, or queried the safety profile of certain medications, asked about the risk of 
MS relapses, and enquired about when to restart medical treatment postpartum. Our 
findings concur with the hypothesis that maternal medicine use is one of the four topics 
pregnant women care about most [18]. We had hoped that all of the topics would have 
been openly discussed with HCPs, but this was not invariably the case. In a number of 
posts, the patient expressed concerns that they had received medical advice from a HCP, 
and either actively disagreed or least significantly doubted what they had been told. For 
example: 
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 ‘’...I went to the infusion center for my first Tysabri treatment, the nurse said my neurologist requested a 
pregnancy test to rule it out before we got started. Long story short, it came back positive! My treatment 
was canceled. Here I am 3 years later, and pregnant with our third baby. Coincidentally, I missed my last 
two months of treatment (I only get it once a month) so it should be well out of my system and there shouldn't 
be any issues...’’ 
In comparison to our results, a Swedish study found that, when speaking with their 
midwives, most pregnant women (70%) did not discuss information that they had 
retrieved online despite perceiving this information to be reliable [19]. Interestingly more 
than half of the study subjects searched online for topics first raised by a midwife [19]. 
We were not in a position to explore the reason why patients went online and searched 
for information about their medicines; however, a web-based survey among women who 
used the Internet to seek pregnancy information showed that 48.6 % of respondents were 
not satisfied with the information provided by their respective HCPs. The majority of these 
respondents (46.5%) stated that they primarily turned to the Internet because they did not 
have time during appointments to discuss their concerns [20]. Moreover, pregnant women 
used the Internet because the information given to them by their HCPs was neither clear 
nor sufficient [20]. 
In the breastfeeding category, 30 out of 70 (42.85%) posts described refusal or delay in 
commencing medical MS treatment for the sake of breastfeeding, or described foregoing 
breastfeeding to restart treatment, or requested evidence of which medication might be 
safer to take whilst breastfeeding, and others commented on discarding breast-milk which 
was suspected to contain medication whilst receiving treatment (so-called ‘pump and 
dump’) [21]. Several individuals shared confusion about the risks and benefits of 
breastfeeding and expressed anxiety about the dilemma of caring for their own health 
whilst not doing any harm to the baby. 
There is very limited information about the safety of MS medication during breastfeeding. 
The in vivo model for drug exposure to breast milk is suboptimal and human milk biobanks 
suffer from a paucity of human breast milk samples [22]. This is paradoxical, particularly 
when one considers the posts concerning the ‘pump and dump’ phenomenon. A small 
adjustment in behavior, based on medical advice or guidance from a midwife, could yield 
a range of useful samples for retention and assay within existing biobanks. In addition, it 
is known that pregnancy registries often have low enrollment rates [23]. In our study, just 
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two posts (2.85%) mentioned contacting pregnancy registries. One possible solution to 
increase the enrollment rate of pregnancy registries and human milk biobank centres 
could be improving the communication to pregnant MS patients about participation both 
at the point of care and in online forums. A simple scripted explanation about the 
existence of registries, the purpose of their research, and the impact that they can have 
on the MS population might yield better recruitment for altruistic reasons. Encouraging 
individuals to participate in the available biobanks with all exhibiting a ‘’pump and save 
rather than pump and dump’’ philosophy after treatment could yield valuable evidence to 
aid decision-making. 
Another important finding was the rate of unplanned pregnancies with 22 out of 70 
(31.42%) posts describing such events, and only eight posts (11.42%) describing planned 
pregnancies. Nonetheless, in some patient information leaflets for MS medicines, both 
contraception and careful planning of pregnancy is clearly recommended [24]. A Danish 
study surveyed 590 MS patients about family planning and reported that 42% of female 
and 74% of male partners did not know if their MS medication was teratogenic or not. 
This study also reported that 10% of pregnancies during MS treatment were unplanned; 
49% of these pregnancies were terminated [25]. 
Generally, there are gaps in current methods for collecting and analyzing data pertaining 
to the safety of medicines during pregnancy and lactation [26,27]. The safety of medicinal 
products administered during pregnancy and lactation is a complex topic that needs 
coordinated communication across many disciplines to obtain, analyze and present 
information in a harmonized approach. Harmonized methods and metrics among different 
pregnancy specialties should be developed to allow better analysis of outcomes and 
endpoints [26]. In this regard, we are aware of an Innovative Medicine Initiative (IMI) 
project called ‘Continuum of Evidence from Pregnancy Exposures, Reproductive 
Toxicology and Breastfeeding to Improve Outcomes Now’ (ConcePTION) [28]. The IMI 
ConcePTION project is a collaboration between public-private partners and the 
pharmaceutical industry in order to address this problem. The aim of ConcePTION is 
‘’Building an ecosystem for better monitoring and communicating safety of medicines use 
in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, 
optimized evidence generation’’ [28]. Participants in this project and the authors of this 
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paper believe that there is an important societal obligation to reduce uncertainty about 
the effects of medicines used during pregnancy and breastfeeding. 
Furthermore, even when safety data are available, it is often not effectively communicated 
to patients and HCPs. On September 26, 2017, the Pharmacovigilance Risk Assessment 
Committee (PRAC) and the European Medicine Agency (EMA) held its first public hearing 
about safety concerns with the use of medications containing sodium valproate during 
pregnancy [29]. Patients and carers participated in the public hearing and both mothers 
and affected children expressed concern about the lack of effective risk minimization 
communication for safety of valproate during pregnancy, despite the drug having been 
authorized for >50 years [30]. After the public hearing, the PRAC and the EMA provided 
new measures for comprehensive risk minimization, including; 
o A pregnancy prevention programme;
o Visual warning about the risk in pregnancy on the box (outer packaging);
o A patient reminder card attached to outer package for pharmacists to discuss with
patients each time the medicine is dispensed;
o Updated educational materials for patients and HCPs [29]
In the valproate pregnancy prevention programme, HCPs are instructed to assess 
patients’ potential for becoming pregnant by evaluating their individual circumstances and 
then assist their patients in making informed decisions. HCPs are responsible for 
informing their patients about the use of effective contraception methods throughout 
valproate treatment and to review such treatment annually. Interestingly, as an adjunct to 
all of these measures, a new risk acknowledgement form has been designed and 
implemented for patients and their HCPs to document that sufficient advice has been 
provided and understood [29]. Such comprehensive guidelines and the risk minimization 
methods adopted for valproate could serve as an example for improving and 
strengthening the warnings for MS medication in pregnancy. 
In 2009, the EMA published guidance for assessing medicinal product risks on human 
reproduction and lactation [31]. In the US, the Food and Drug Administration (FDA) issued 
the Pregnancy and Lactation Labeling Rule (PLLR) for industry. This document provides 
a detailed framework for clearly communicating information to prescribers to aid improved 
decision making [21,32]. It is worth noting a study that reviewed medication risks during 
pregnancy for 172 drugs approved by FDA between 2000 and 2010. Among these, in 
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97.7% of drugs teratogenic risk in human pregnancy was “undetermined’’ and amount of 
data for 73.3% of these drug was described as ‘’none’’ [33]. For 468 drugs approved by 
FDA between 1980 and 2000, the average time required for a drug’s risk category to be 
changed from ‘’undetermined’’ to a more precise risk was estimated to be 27 years [33]. 
A web-based survey reported that patient leaflets were not comprehensive enough to 
answer pregnant women’s questions and did not facilitate decision-making [20]. In 
addition, inconsistencies have been found between the safety information concerning use 
during pregnancy provided in the US prescribing information and the UK summary of 
product characteristics for the same medical product [8]. 
Evidently, there is a need to improve regulatory policy and guidance by involving not only 
health authorities, but also HCPs, patients and other stakeholders including the national 
Teratology Information Services. Two recommendations we suggest are to conduct active 
post-marketing surveillance and to provide globally harmonized evidence-based 
information for the prescriber, patients and carers in a timely manner. Inevitably, with the 
Internet and the wide variety of social media available, information is rapidly disseminated 
and patients have access to, and appear to trust non-traditional sources of medical 
information. We anticipate that in future it will not be permissible to take three decades to 
vary existing labelling once sufficient evidence has been generated to provide useful 
information to patients and prescribers. 
Conclusion 
Social media can provide insight into patients’ real life experiences with medical products 
during pregnancy as well as their struggle in comprehending the benefits and risks that 
this poses. Our study showed that MS patients expressed uncertainty and concerns 
around reproductive health; however, social media could be utilized as a platform to 
engage and encourage patients to enroll in pregnancy registries and to donate samples 
to milk biobank research centers. The adoption of these simple methods would support 
the generation of essential missing safety data, and would support the communication of 
risk minimization strategies to pregnant patients and women of childbearing potential [34]. 
The role of HCPs involved in supporting pregnant patients, or during early child 
development, should not be underestimated. HCPs could provide comprehensive 
information for MS patients throughout different stages of pregnancy and postpartum, as 
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well as during breastfeeding. Additionally, improving safety data collection and analysis 
as well as implementing efficient policies in regards to practical guidelines for MS 
populations of childbearing age would prove advantageous. Future guidelines should 
address the impact of MS on pregnancy and the effect of pregnancy on MS, the risks of 
the occurrence of birth defects, recommendations concerning the most effective 
contraceptive methods, and planning pregnancy as far as possible, in order to allow 
optimal wash-out time of medication, disease control during and after pregnancy, 
approved medication to use in reproductive periods and lactation guidelines following the 
treatment [2,35]. Further research is needed to explore the effectiveness of risk 
minimization methods and to improve communication among HCPs and patients to the 
extent that it enables and informs shared decision-making. 
Limitations of the Study 
Social media surveillance for medical product insight poses multiple challenges which 
has been addressed in literature [10,11,13]. In summary, there are technical, regulatory, 
privacy and ethical considerations that need to be addressed when leveraging social 
media for this purpose [11]. In this study, the classifier was specifically selected to conduct 
research focusing on the exposure to MS medicines, not the effects of MS disease on the 
outcomes of pregnancy. In addition, these searches were only performed in pregnancy 
forums where posts related to MS medications were published. Hence, we recommend 
that further research to be conducted in both MS and other disease-specific forums 
including ‘multiple sclerosis’ term. 
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Product Synonyms 
alemtuzumab alemtuzumab, Lemtrada™ 
teriflunomide teriflunomide, Aubagio™ 
interferon beta-1a interferon beta-1a, Avonex™, Plegridy™, Rebif™ 
interferon beta-1b interferon beta-1b, Betaferon™, Betaseron™, Ferona™, Extavia™, 
Compesk™ 
glatiramer acetate glatiramer acetate, Copaxone™, Glatopa™ 
daclizumab Daclizumab 
dimethyl fumarate dimethyl fumarate, Tecfidera™ 
fingolimod fingolimod, Gilenya™ 
natalizumab natalizumab, Tysabri™ 
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Abstract 
Patient safety during pregnancy is an important concern. This article presents a method 
of using an industry post-marketing database to access prospective pregnancy cases. 
This method, termed ‘PRegnancy outcomes Intensive Monitoring’ (PRIM) was 
developed for fingolimod (Gilenya TM), a treatment option for multiple sclerosis (MS), 
due to slow enrollment in the company pregnancy registry. The aim of PRIM was to 
enhance the process of pregnancy data collection and improve data quality, and in turn 
particular to enable estimation of the proportion of major congenital malformation and 
other pregnancy outcomes. To do this, the spontaneous reports of fingolimod maternal 
exposure or in the eight weeks immediately before the last menstrual period reported to 
the safety database but not enrolled in the pregnancy registry were identified. Follow up 
checklists were sent at four time points: initial pregnancy report, end of pregnancy, and 
infant follow-up at 3 and 12 months of age. These focused on core data required for 
derivation of programmed analyses. From 01 Mar 2014 to 28 Feb 2018, a total of 831 
prospective maternal exposures with 843 infants were reported, with fetal outcomes 
reported in 459 (54.4%) of those infants. This enabled the calculation of proportions of 
pregnancy cases with the main pregnancy outcomes and of fetal cases with 
malformation. The number of reported 
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pregnancies was significantly higher in PRIM than in the registry, showing that 
structured use of pharmacovigilance data could enables speedier assessment of risks of 
maternal drug exposure.
 Keywords 
Pregnancy outcome; Intensive monitoring; Targeted follow-up; Pharmacovigilance; 
Multiple sclerosis; Maternal exposure
1 Introduction 
1.1 Background 
Pregnant women are usually excluded from clinical trials for ethical reasons. 
Therefore, at the time of marketing authorization safety data of medical products in 
pregnant women are usually limited to animal data (1). Post-marketing surveillance 
methods such as pregnancy registries are sometimes required by health authorities in 
order to characterize the outcomes of the use of medicines in human pregnancy (2). 
Collection of spontaneous reports is a legal requirement of all marketing authorisation 
holders; information on all cases of pregnancy associated with exposure to a 
medicinal product for which the marketing authorization holder (MAH) has a 
pharmacovigilance responsibility is collected and processed in order to provide data of 
the required quality for assessment (3,4). Pregnancy registries have been considered 
as the preferred method to collect safety information on human exposure to 
authorised medicines during pregnancy. Registries have well-documented 
advantages such as providing structured studies, supported by customized 
databases. But they also have important limitations including difficulties in enrolling 
patients and poor follow-up rates, which in turn results in high costs and delays or even 
complete failure to obtain meaningful results regarding the outcomes of the use of 
medicines in pregnancy (2,5,6) . Delays in providing such information has an impact 
on public health. A good example is valproate which was first approved in 1978 (7). 
The Pharmacovigilance Risk Assessment Committee (PRAC) held a public hearing to 
discuss this product in January 2015 in order to further inform stakeholders about the 
impact of its use during pregnancy. As a result, the European Medicines Agency 
(EMA) and National Competent Authorities across Europe have informed healthcare 
professionals and patients of the high risks of valproate concerning congential 
malformations and 
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neurodevelopmental delay in the infant. A series of new pregnancy prevention and risk 
minimization measures were established (8). A systematic review of pregnancy registries 
for 34 products showed a median registry enrollment of 36 pregnancies compared with a 
median of 450 spontaneous reports of pregnancy exposure received by manufacturers 
contemporaneously (9). The same study reported that for products rarely used in 
pregnancy, the worldwide spontaneous reporting rate was much higher than the registry 
enrollment rate (9). However, despite the fact that receipt of spontaneous reports is high 
compared with enrollment into registries, spontaneous report data are collected passively 
relying on healthcare professionals and patients to submit reports, so the information 
received is often insufficiently complete or not of the required quality and consistency for 
data aggregation and programmatic analysis.  
In addition to these issues, there is insufficient harmonization of terminologies, methods 
of assessment, and standardization of data elements with respect to safety interventions 
in pregnancy. Innovative solutions are required to provide enhanced safety data collection 
and pharmacovigilance (10). 
1.2 Multiple sclerosis and fingolimod  
MS is an immune-mediated inflammatory disorder of the central nervous system (11) The 
gender ratio is different depending on the subtype of MS; relapsing remitting multiple 
sclerosis (RRMS) has a female-to-male ratio of 2-3:1 (12). The average age of onset of 
MS is 29.2 years indicating that many MS patients are women of childbearing age when 
diagnosed with the disease (13). Fingolimod (GilenyaTM) is indicated as a disease-
modifying therapy for the treatment of patients with relapsing type of MS. In animal 
models, it was shown that fingolimod (5.0 mg/kg orally) and its metabolites cross the 
placental barrier in pregnant rabbits to a limited extent (14). Fingolimod was found to have 
a teratogenic effect in rats including persistent truncus arteriosus and ventricular septal 
defect (14). Before initiation of treatment with Gilenya in women of childbearing potential, 
a negative pregnancy test result needs to be available and counselling should be provided 
regarding the potential for serious risk to the foetus and the need for effective 
contraception during treatment with Gilenya (14). 
In response to the need for prospective follow-up data in human pregnancy, the Gilenya 
Pregnancy Registry (referred to as the Registry) was established, with the first patient first 
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contact on 15 Oct 2011 (EU PAS register number: ENCEPP/SDPP/2569) (15). The 
purpose of the Registry was to collect more safety data on the risk of reproductive toxicity 
of fingolimod exposure during or shortly before pregnancy. However, due to slow 
enrollment in the Registry (15), the routine pharmacovigilance (PV) process was 
accessed to collect more data on spontaneous reports of pregnancy exposed to 
fingolimod received in the company safety database. However, it was recognized that not 
all registry variables would be available from spontaneous reports, therefore PRIM was 
designed in order to focus on the most important data to support medical assessment 
(namely core data on the mother, on the pregnancy outcome, and on the fetal and infant 
outcomes) needed to quantify the risks of reproductive toxicity. 
The objective of PRIM was to establish an enhanced pharmacovigilance method by 
improving collection, quality, and processing of prospective data from spontaneously 
reported pregnancies reported to the global safety database, to enable computer 
programmed estimation of the proportion of infants/fetuses with major congenital 
malformation and of other pregnancy outcomes such as stillbirth and termination of 
pregnancy.  
2 Methods 
2.1 PRIM description 
The PRIM (PRegnancy outcomes Intensive Monitoring) was defined as enhanced 
pharmacovigilance data collection and processing via sets of targeted checklists, 
structured follow-up, rigorous process of data entry and data quality control, and 
programmed aggregate analysis. This enhancement was initiated on 01 March 2014 for 
fingolimod to access data from pregnancies prospectively reported to the MAH safety 
database in patients who were not enrolled in the Registry. To reduce bias in these 
estimates, the process focused on prospectively-reported pregnancies. 
Differences between PRIM and routine PV for pregnancy case follow-up are summarised 
in Table 1. PRIM was established as an end-to-end process including determining crucial 
outcomes of interest, definition of terms, data collection and follow-up, data processing 
and analysis. Table 2 shows each step of PRIM methodology.  
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Table 1 The PRIM (PRegnancy outcomes Intensive Monitoring) and routine 
pharmacovigilance procedure for pregnancy cases  
PRIM Routine pregnancy pharmacovigilance 
procedure  
Data collection points: Baseline, EDD a +1 month, 
EDD+ 3months and EDD+12 months 
Data collection points: Baseline, EDD+1 month; 
EDD+3 months, EDD+ 12 months 
Four follow-up (FU) attempts at each data 
collection point before a patient would be 
considered lost to follow-up 
Three FU attempts at outcome of pregnancy (no 
information received after sending EDD+12 
months follow-up) before a patient would be 
considered lost to follow-up 
For specific Patient Oriented Programs (POP) with 
continuous interactions with patients, Novartis or 
External service provider collects the necessary 
FU information (when allowable by local 
regulations and program design) by contacting the 
reporter through all possible means (i.e. phone, e-
mail, letter, fax etc.) 
Data collections from POP would be as per routine 
process i.e. spontaneous reporting 
Automated check of overdue FUs by central site 
which contacts Novartis local affiliates directly with 
long overdue FU (>30 days) 
Check of overdue FUs by Novartis local affiliates 
only 
Data collection and follow-up on normal infants not 
just those reporting adverse events (AEs)/ 
malformations 
Data are usually reported only on adverse 
pregnancy or fetal outcomes 
Adjudication of cases of malformation and 
categorization of major, minor, or other by an 
external expert panel 
No adjudication of cases of major malformation  
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Enhanced data quality control and data correction 
focusing only on crucial data needed for 
programmed statistical data aggregation 
Data quality and control as per the routine 
pharmacovigilance process 
Programmed data extraction and aggregate 
analysis detailed in a Statistical Analysis Plan 
Manual intervention needed to produce outputs 
a) EDD: Estimated delivery date
Table 2 The PRIM end-to end process steps 
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Sequential step Details 
Regulatory / Scientific 
objectives  
Determine the specific objectives on reproductive toxicity to be addressed to 
regulatory authorities and/or scientific bodies (e.g. prevalence of major 
malformation, or pregnancy outcomes such as stillbirth etc.)  
Summary data tables / 
Core statistics 
Determine the content of all required data summary tables. 
Core data selection Selection of raw and derived data needed for required data tables.  
Core data definition Define each core data element for consistency 
Database structure Define data fields for core data elements needed to create analysis datasetsa. 
Define any necessary customization of the safety databaseb 
Data source Define the set of cases in the safety database for inclusion in PRIM 
Targeted data 
collection forms  
Define type, format, layout, content of the targeted follow up checklist. 
Ensure that the checklist can collect all fields needed to create analysis 
datasets and that the format encourages complete and accurate data.  
Data collection  Define initial and follow-up data collection process including the method of 
distribution and receipt of completed data collection tool. Define case 
adjudication process  
Data entry and quality 
control 
Define clear rules for data transfer from the completed data collection 
checklist to the safety database 
Determine and apply data quality control tools 
Data analysis Perform programmed data extraction and aggregate analysis via 
programmed algorithms according to statistical analysis plan with no manual 
interventions 
a) Programming of data retrieved for fingolimod was in SAS™ software b) Novartis uses the Argus Safety™ spontaneous report safety 
database 
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2.2 Regulatory / Scientific objectives  
Following the EMA recommendations (EMEA/CHMP/313666/2005) (4), pregnancy 
outcomes were defined in two groups of primary and secondary outcome as described 
below. Importantly, in the PRIM full data on pregnancies with a normal outcome were also 
collected to ensure an overall denominator for estimation of the prevalence of major 
malformations. 
The primary pregnancy outcome of interest was the occurrence of major congenital 
malformations in the offspring. In addition, pregnancy outcomes such as live birth, 
spontaneous abortion, stillbirth, elective termination, and ectopic pregnancy were 
collected. Prevalence of such outcomes was calculated.  
The following adverse pregnancy outcomes were also collected: 
Minor malformation; which are anomalies with no serious medical or cosmetic 
consequence to the child 
Data on infant adverse events such as infections and developmental milestones at three 
months and one year of age were collected. 
2.3 Summary data tables / Core Statistics  
Descriptive and quantitative analysis of the data were conducted, supplemented by 
medical analysis of individual cases. The number of reports with specific pregnancy 
outcomes (for example, major congenital malformations, minor congenital malformations, 
spontaneous abortions, stillbirths, elective terminations), was presented. Reporting 
proportions of outcomes were calculated. Prevalence estimates of major malformation in 
live births and in live births, stillbirths, and termination of pregnancy due to fetal anomaly 
(TOPFA) were calculated with exact 95% confidence interval (CI). Format and content of 
summary tables of core statistics were designed to address core regulatory / scientific 
research statements, specifically: case disposition, case demography, timing of 
exposure, pregnancy outcome, estimated prevalence of major malformation. All analyses 
was performed using SASTM version 9.2.  
2.4 Core Data selection 
Core data were selected carefully based on what was needed for derivation of core 
statistics for tabulation to answer regulatory objectives. The list was adjusted to find a 
balance between reporting requirements and feasibility considering the structure of the 
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safety database and the likelihood of obtaining high-quality data. The more important core 
data are outlined in Table 3. Such lists for other products, might differ depending on 
alternative research objectives and data sources like claims databases, electronic 
medical records and registries. Guidance documents from regulatory authorities (e.g., 
EMA and FDA) should also be considered. 
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Table 3- Core data  
Case 
identification 
Product 
exposure 
Pregnancy and  
fetal outcome 
Infant follow up 
(3 and 12 
months) 
Maternal risk 
factors 
Mother case 
identifier 
Product name(s) Pregnancy status: 
known  
pending  
unknown (lost to 
follow up) 
Outcome specific 
for product/ 
disease  
Pre eclampsia, 
Eclampsia 
Gestational diabetes 
Baby case 
identifier 
Product start 
date 
Pregnancy 
outcome: 
Live birth 
Still Birth 
Termination (e.g. 
spontaneous  
abortion) 
 
Sign of 
developmental 
delay  
Chronic disease: 
Hypertension 
Diabetes 
Epilepsy 
Infections 
Thyroid disease 
Autoimmune 
disease 
Case receipt 
data 
Product stop 
date 
Number of fetuses Infections Smoking  
Alcohol use  
Use of Recreational 
drugs 
Demographic 
data 
Exposure during 
washout period 
of drug (Pre-
LMP) 
Mode of delivery 
(vaginal, C-section, 
etc.) 
Malformation not 
detected at birth 
Concomitant 
medication  
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Date of LMPa or 
EDD 
Date of delivery 
/ end of 
pregnancy 
Trimester 
exposure (1st, 
2nd , 3rd) 
Newborn  
demographics 
 
 Obstetric history 
 
Pre-natal test(s) 
result(s) 
Dose and Route Congenital 
malformation 
Major or minor 
 
 
 Family history of 
birth defect and 
degree of relation 
ship 
a) LMP: Last menstrual period, EDD: Estimated date of delivery 
2.5 Core data definition 
Definition of terms for the core data elements was established to ensure consistency 
across and within pregnancy datasets. 
2.5.1 Prospective case definition 
In PRIM, only prospective pregnancies were considered for analysis and follow-up. 
Different definitions of a prospective pregnancy case are suggested by the EMA, FDA, 
and other bodies. For PRIM, the EMA definition from GVP Module VI; of a prospective 
pregnancy case was used, (4) because this is also the standard in the Argus safety 
database. Table 4 shows the definition used in PRIM and the variation used in the 
Novartis pregnancy registry (16).  
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Table 4 Prospective case definition from different sources 
Timing and results of prenatal testing PRIM (based on 
EMA definition) 
Gilenya pregnancy 
registry (based on 
FDA definition) 
Pregnancy outcome has not occurred and prenatal 
tests have not been performed at the time of reporting 
or enrollment (entry)a 
Prospective Prospective 
Prenatal testing was performed at the time of entry, 
result of congenital malformation have not been 
received by provider/patient/Novartis or results were 
normal 
Prospective Retrospective 
Prenatal test results were available and were known 
to be abnormal at the time of entry 
Retrospective b Retrospective 
a) ‘Entry’ is considered the date of initial report received by Novartis for PRIM cases, and entry is considered date of enrollment/signed 
informed consent for the registry. 
 
2.5.2 Pregnancy periods for analysis  
The following basic periods can be defined: 
• Peri-LMP: within 8 weeks prior to LMP 
• First Trimester: from LMP to 12 weeks (≥ 0 days to < 84 days) of gestation 
• Second Trimester: from 12 weeks to 26 weeks (≥ 84 days to < 182 days) of 
gestation 
• Third Trimester: from 26 weeks (≥ 182 days) of gestation until end of pregnancy 
The eight-week peri- LMP timeframe was set specific to fingolimod to cover the wash-out 
period of medicine considering the four-week half-life of product. 
Exposure to the product of interest in any of these four periods could be derived from the 
date of LMP and drug start/stop dates (if complete), targeted questions asking about 
exposure in each period, but may also be logically determined from narrative text. 
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2.5.3 Categories fetal exposure for analysis 
Information on occurrence of exposure in one or more of these four pregnancy periods 
can be combined if considered more informative. For fingolimod the following categories 
were used when describing fetal exposure: 
• Only peri-LMP; exposure was reported only in the peri-LMP period 
• At least first trimester; exposure was reported in the first trimester but possibly also 
in other categories 
• Only after the first trimester; exposure was reported only after the end of the first 
trimester 
• Exact timing of exposure in pregnancy is unknown 
2.6 Database structure 
All core data elements needed to create analysis datasets must be mapped to a defined 
data field of the safety database. This allowed efficient automated data extraction via 
programming with no manual intervention. Where needed, available fields in the existing 
safety database structure were customized to capture those elements.  
2.7 Data sources 
Cases reported to the Argus database that were selected for PRIM were those reported 
from spontaneous post-marketing report sources, post-marketing observational studies 
and patient support programmes, and reports from the Novartis clinical trials programme. 
Crucially, PRIM included only pregnancy cases with a documented exposure to 
fingolimod during pregnancy; these cases were associated with the Medical Dictionary 
for Regulatory Activities (MedDRA) preferred term (PT) ‘maternal exposure during 
pregnancy’.  
Exclusion Criteria: The following cases were excluded from the PRIM dataset: 
• Retrospective reports of pregnancy  
• Reports of male partners taking fingolimod 
• Reports in which the woman discontinued fingolimod before the 8 weeks washout 
timeframe (> 8 weeks prior to LMP) 
• Reports included in the Registry; these were excluded to avoid case report duplication 
(fingolimod-specific) 
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• Reports reported before 01-Mar-2014 (fingolimod-specific) – start of PRIM.  
2.8 Data collection 
2.8.1 Follow up checklist 
The follow-up checklist used for fingolimod on collection of the required core data. 
Information was to be collected from reporters at four time points as summarized in Table 
5. Each time point was set based on pharmacovigilance requirements as well as time 
points requested by health authorities specifically for fingolimod (e.g., to collect data on 
infections and the achievement of developmental milestones within the first year of life of 
the offspring) but the timings could be adjusted to any product and its potential or 
identified risks. The checklists were sent for the mother and the offspring separately, 
aiming to collect the maternal, fetal, and neonatal data. 
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Table 5 Case follow-up 
Follow-up 
number 
Checklist name Type of information 
collected 
Timing Attempts cycle (in 
case of no response) 
FU 1 Baseline Baseline 
characteristics and 
demographics of the 
mother  
 
As soon as possible after 
initial pregnancy report, or 
at initial report if possible 
At least 4 attempts, at a 
minimum of 1 week and 
maximum of 1 month 
apart, unless EDDa is  
reached (in such case 
merge FUs 1 and 2) 
FU 2 Pregnancy 
Outcome 
Information related to 
the end of pregnancy,  
delivery, and neonate 
 
Between EDD and 
EDD+30 days 
At least 4 attempts, at a 
minimum of 1 week and 
maximum of 1 month 
 FU 3 Infant health status 
at 3months 
Information related to 
infant health status 
and development 
EDD + 3 months At least 4 attempts, at a 
minimum of 1 week and 
maximum of 1 month 
 FU 4 Infant health status 
at 12 months 
Information related to 
infant health status 
and development 
EDD + 12 months At least 4 attempts, at a 
minimum of 1 week and 
maximum of 1 month 
 
a) EDD: estimated delivery date 
 
To enhance completeness of data, four attempts were made to collect data from the 
reporter. After the initial checklist was sent, reports with incomplete or missing data 
received follow-up attempts from the Novartis local affiliates on a monthly cycle. Reports 
were considered lost to follow-up 30 days after the fourth documented unsuccessful 
attempts to collect follow-up information or in case the reporter refused further contact. 
Automated checks for overdue FUs were performed and listings of any overdue FUs were 
generated centrally; requests for action were distributed to county affiliates in order to 
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complete the information gathering process. Reports of live births were considered 
complete when data regarding the pregnancy outcome (primary outcome) and the infant 
outcomes at one-year of age were received. Where the reported outcome was not a live 
birth, only the pregnancy outcome FU checklist was sent.  
2.8.2 Adjudication process 
Adjudication of individual cases of reported congenital abnormality or developmental 
delay was performed by an independent external panel of three experts. Two teratologists 
were responsible for adjudication of individual cases. The third independent expert 
(Neurologist) was contacted in case of different opinions by the two adjudicators. This 
panel was selected from a list of available experts in the field of teratology and 
reproductive toxicology and with no affiliation to Novartis. Adjudicators evaluated the data 
to determine whether the malformation was major or minor using the European 
Surveillance of Congenital Anomalies (EUROCAT) definitions. Major malformations are 
defined as any structural defects with recognized surgical, medical, or cosmetic 
importance (17). If the report had insufficient information for adjudication it was classified 
as “congenital anomaly not otherwise specified (NOS)”. 
2.10 Data entry in the safety database  
Data collected through the targeted checklists were entered into the company safety 
database. Infant/fetus and maternal AEs were coded using MedDRA [version 20.1], 
mapping verbatim terms to the MedDRA hierarchy. Where multiple abnormalities were 
reported in the neonate all AEs were recorded in order to ensure completeness of content 
for the medical evaluation. Only the most significant malformation was counted in the 
prevalence estimation. 
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2.11 Data Quality 
Quality control of data entered to the company safety database was performed according 
to the standard operational procedures for pharmacovigilance. Additional checks focusing 
on core data elements were performed in order to improve data quality and support 
programmatic data summarisation. As a result extra guidelines were imposed, and 
additional training was provided for the designated case processing team.  
3 Results  
Analysis of cumulative fingolimod pregnancy outcome data from 01 March 2014 to 28 
February 2018 extracted from the global safety database for individual case safety reports 
(ICSRs) defined for PRIM are presented in this section to illustrate the PRIM concept. 
The focus is on the method rather than illustration of the safety profile of the product.  
 
3.1 Case disposition and exposure during pregnancy  
Overall, 831 prospectively reported pregnancy cases and 843 infants/fetuses (12 sets of 
twins) met the definition for the PRIM process. The follow-up status of these ICSRs is 
presented in Table 6.  
Table 6 Case disposition 
Case distribution Cases  
Total prospective pregnancy cases 831 
Total infant cases 843  
• Pregnancy - outcome known 459 (54.4%)  
• Pregnancy - outcome pending 136 (16.1%) 
• Lost to follow-upa 248 (29.4%) 
a) Birth-type not known. Permission or contact information for report was not provided or all attempts to obtain outcome information 
per PRIM guidelines were exhausted 
 
The 16.1% of pending reports mainly comprise pregnancies not yet having an outcome 
at data cut-off. A summary of fetal exposure to fingolimod is provided in Table 7. Timing 
of exposure was reported for 826 (98.0%) of the 843 fetuses. In 17 fetuses, exact timing 
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of exposure during pregnancy was unknown although exposure to fingolimod was known 
to have occurred during the pregnancy. In pregnancies with a known birth-type outcome, 
timing of exposure was reported for 455 (99.1%) of the 459 fetuses. 
Table 7 Fetal exposure to fingolimod 
Timing of exposure in pregnancy All Cases 
N = 843  
 n (%) 
Cases with Known Pregnancy 
Outcome 
N = 459  
n (%) 
Peri-LMP onlya 46 (5.5) 32 (7.0) 
At least first trimesterb 779 (92.4) 423 (92.2) 
Only after first trimesterc 1 (0.1) 0  
Exact timing in pregnancy unknown 17 (2.0) 4 (0.9) 
Other categories 0  0  
a) Exposure was reported only in the peri-LMP period (within 8 weeks prior to LMP) 
b) Exposure was reported in the first trimester but possibly also in other categories 
c) Exposure was reported only after the end of the first trimester 
3.2 Demographic data 
A summary of baseline demographic characteristics is presented in Table 8. Patients had 
a mean age of 31 years. They were primarily Caucasian but ethnicity and pre-pregnancy 
body mass index (BMI) were under-reported. 
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Table 8 Maternal demographics for all maternal cases  
Demographic variable 
Category Statistic 
Mother cases  
N = 831a (%) 
Age at LMPb (years) 
n (%) 588 (70.8) 
Mean (SD) 31 (5.6) 
Median (min, max)  31 (17, 47) 
Ethnicity 
n (%)  294 (35.4) 
Caucasian 226 (76.9) 
Black 19 (6.5) 
Asian 10 (3.4) 
Hispanic 10 (3.4) 
Oriental 2 (0.7) 
Other 25 (8.5) 
Unknown 2 (0.7) 
Region 
n (%) 831 (100) 
Europe 369 (44.4) 
Canada/US 274 (33.0) 
Japan 18 (2.2) 
Other 170 (20.5) 
Pre-pregnancy BMI (kg/m2)c 
n (%) 331 (39.8) 
Mean (SD) 26.1 (6.05) 
n = number of cases with non-missing data.  
a) All cases with demographic information are included, including all outcomes and lost to follow-up cases. 
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Demographic variable 
Category Statistic 
Mother cases  
N = 831a (%) 
b) Age as reported or calculated based on date of birth and LMP; if LMP is not available, age was based on date of birth and 
manufacturer’s receipt date. 
c) BMI may correspond to the time of reporting, which may be in the early stages of pregnancy. BMI is calculated using the following 
formulas, based on reported units of measurement: (Weight (lbs.) ∕ (Height (in) × Height (in)) × 703) or (Weight (kg) ∕ (Height (cm) 
× Height (cm)) × 10 000).  
3.3 Pregnancy outcomes 
Birth type and fetal outcome for 459 infants/fetuses from pregnancies with known 
outcome are summarized in Table 9. Results are shown overall but also by pregnancy 
period and the number of cases of malformation could be described for each main 
outcome type. There were no stillbirths or ectopic pregnancies reported. 
Table 9 Summary of pregnancy outcomes by timing of exposure to 
fingolimod; infants/fetuses with known birth type 
 
Birth type 
Fetal outcome 
Peri-
LMP 
onlya 
n (%) 
At least 
firstb 
trimester 
n (%) 
Only after 
first 
trimester 
n (%) 
Exact timing in 
pregnancy 
unknownc 
n (%) 
Overall 
n (%)  
All pregnancies with known 
birth type 
32 
(100) 
423 (100) 0 4 (100) 459 
(100) 
Without reported congenital 
malformations  
31 
(96.9) 
409 (96.7) 0 4 (100) 444 
(96.7) 
 Congenital 
malformations 
1 (3.1) 14 (3.3) 0 0 15 (3.3) 
  Major  1 (3.1) 7 (1.7) 0 0 8 (1.7) 
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  Minor  0  3 (0.7) 0 0 3 (0.7) 
  Unspecifiedd 0 4 (0.9) 0 0 4 (0.9) 
Ectopic pregnancy 0 0 0 0 0 
Spontaneous abortione 3 (9.4) 61 (14.4) 0 0 64 
(13.9) 
Elective termination 3 (9.4) 74 (17.5) 0 0 77 
(16.8) 
 Without reported 
congenital malformations  
2 (66.7)   72 (97.3)  0  0  74 
(96.1)   
 Congenital 
malformations 
1 (33.3) 2 (2.7) 0  0  3 (3.9)   
  Major  1 (33.3) 1 (1.4) 0 0  2 (2.6)   
  Minor  0 0  0  0    0  
  Unspecifiedd 0 1 (1.4) 0 0  1 (1.3)      
Stillbirth 0 0 0 0 0 
 Without reported 
congenital malformations  
0 0 0 0 0 
 Congenital 
malformations 
0 0 0 0 0 
  Major  0 0 0 0 0 
  Minor  0 0 0 0 0 
  Unspecifiedd 0 0 0 0 0 
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Live birth 26 
(81.3) 
288 (68.1) 0 4 (100) 318 
(69.3) 
 Without reported 
congenital malformations 
26 
(100) 
276 (95.8) 0 4 (100) 306 
(96.2) 
 Congenital 
malformations 
0  12 (4.2) 0 0 12 (3.8) 
  Major  0  6 (2.1) 0 0 6 (1.9) 
  Minor  0 3 (1.0) 0 0 3 (0.9) 
  Unspecifiedd 0 3 (1.0) 0 0 3 (0.9) 
Live births, stillbirths, and 
TOPFA 
27 
(84.4) 
290 (68.6) 0 4 (100) 321 
(69.9) 
 Without reported 
congenital malformations 
26 
(96.3) 
276 (95.2) 0 4 (100) 306 
(95.3) 
 Congenital 
malformations 
1 (3.7) 14 (4.8) 0 0 15 (4.7) 
  Majorf  1 (3.7) 7 (2.4) 0 0 8 (2.5) 
  Minor  0 3 (1.0) 0 0 3 (0.9) 
  Unspecifiedd 0 4 (1.4) 0 0 4 (1.2) 
a) Exposure was reported only in the peri-LMP period 
b) Exposure was reported in the first trimester but possibly also in other categories 
c) Exposure was reported only after the end of the first trimester 
d) Unspecified malformations = congenital anomaly NOS 
e) Spontaneous abortion includes fetal outcome cases of Fetal death /intrauterine death and blighted ovum 
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f) 1.Congenital cardiac septal defect, 2.Fallot’s tetralogy and congenital pulmonary valve atresia, 3.Oesophageal atresia and atrial 
septal defect, 4. Congenital ureteric anomaly and congenital hydronephrosis, 5. Cryptorchism, 6. Corpus callosum agenesis, 
7.Trisomy 21, 8. Embryo overt spina bifida and banana- shaped skull. 
3.4 Prevalence of major congenital malformations 
The estimated prevalence of major congenital anomalies (including chromosomal 
anomalies or genetic disorders), adjudicated according to EUROCAT definitions, could 
be calculated; 1.89 % (95% CI 0.70, 4.06) in live birth, and 2.49% (95 % CI 1.08, 4.85) in 
live births, stillbirths, and TOPFA. 
3.5 Individual case safety reports of infant adverse events 
The programmed algorithms identified groups of neonates for individual case 
assessment. AEs were reported in 15 of the 310 infants without reported congenital 
malformations. Overall, the AEs reported were heterogeneous with no evidence of a 
safety signal of infant AEs in the first year of life. The infant AE “small for dates” or “small 
for gestational age” was reported in one full term birth and three preterm births. One infant 
was reported to have motor developmental delay and one had an unspecified 
developmental delay; both infants were born prematurely.  
Discussion 
A systematic review confirmed the well-document challenges of operating pregnancy 
registries and thus emphasised the need for complementary or alternative methods (5). 
Because post-marketing data are the main data source for safety of medicines in 
pregnancy, better post-marketing surveillance methods can enhance the assessment of 
pregnancy exposures and thereby yield meaningful information on outcomes and adverse 
or risks in a shorter time-frame than traditional registries.  
PRIM showed that information can be collected faster and from a larger patient population 
than a registry and with a better quality than that of conventional spontaneous reports. In 
order to conduct an informed medical assessment, good quality ICSRs are required 
containing important data elements as described in Table 3. PRIM enhanced data 
collection by establishing targeted checklists focused on data completeness and data 
quality of the core data needed for reporting essential statistics to regulatory and other 
scientific bodies. Mother’s age at LMP was available for 70% of the ICSRs, but by 
comparison BMI for only 39.8%, and ethnicity for 35%. Remarkably the timing of exposure 
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to fingolimod during pregnancy was reported for 98.0% of the 843 fetuses, increasing to 
99.1% of the 459 fetuses from pregnancies with a known birth-type outcome. 
In our example, the pregnancy outcome was known for 54.4% of cases, 16.1% pending 
outcome and 30% of all ICSRs were lost to follow-up as such there may be selection bias 
for pregnancies with documented outcomes versus those that were not documented. This 
selection bias may be either towards the presence of adverse pregnancy outcomes or 
towards a particular subgroup of women who have higher healthcare seeking behavior. 
It is also thought that the seriousness of an adverse event contributes to whether or not 
it is reported, with serious events more likely to be reported than non-serious events (18). 
Some of the known limitations of spontaneous reports that pose considerable challenges 
for analysis are the lack of a denominator and gaps (null values) in essential data fields 
(19). However, this enhanced pharmacovigilance method ensures a denominator for the 
calculation of proportions (for example of spontaneous abortions among all pregnancies 
or of major congenital malformations in live births) by prospectively following up and 
collecting maximum data on all pregnancy cases regardless of their outcome. Incidence 
of birth types and fetal outcomes including malformation classified as major, minor and 
unspecified outcome could therefore be calculated and prevalence of major 
malformations estimated. Keeping in mind that PRIM like other non-interventional studies 
(e.g. registry) represents the reported population rather than exposed population. 
The results obtained using PRIM (a subset of fingolimod pregnancy safety data) enabled 
an estimation of the prevalence of major congenital malformation for live birth (1.89% 
(95% CI, 0.70-4.06)) and for live birth, still births and TOPFA (2.49% (95% CI, 1.08-4.85)), 
that could be compared with general population data, in which the prevalence of major 
malformations varied between 2.0% (95% CI, 2.0-2.1) (20) and 4.5% (95% CI, 4.5-4.5) 
for live births(21). The range for live births, stillbirths and TOPFA wwas 2.6% (95% CI, 
2.6-2.6) (20) to 6.9% (95% CI, 6.6-7.2) (15,20).  
A study that reviewed medication risks during pregnancy for 172 drugs approved by FDA 
between 2000 and 2010 reported that in 97.7% of drugs the teratogenic risk in human 
pregnancy was “undetermined’’ and amount of data for 73.3% of these drug was 
described as ‘’none’’ (22). For 468 drugs approved by FDA between 1980 and 2000, the 
average time required for a drug’s risk category to be changed from ‘’undetermined’’ to a 
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more precise risk was estimated to be 27 years (22). Experiences from other MS and 
non-MS medicinal products have indicated that treatment-specific registries have mostly 
failed to deliver timely and robust information and the limited amount of evidence accrued 
in these registries has not been helpful in deciphering the reproductive toxicities risk 
associated with these products (9,23). Despite all efforts Novartis has experienced similar 
recruitment challenges with the Registry. The PRIM process for fingolimod included 
almost six times (674 prospective cases) as many prospective pregnancies (113 case) in 
four years as the Registry had enrolled in seven years (15).  
There is a need to make better scientific use of existing PV systems to collect data and 
thereby facilitate the medical evaluation process. This will better inform decisions 
concerning the communication of outcome information following exposure to medicines 
during pregnancy. Thus enhanced pharmacovigilance studies such as the PRIM can 
support the provision of evidence-based information in timely manner which will in turn 
enable patients and healthcare professionals to make informed choices. This method 
could be complementary to or potentially an alternative to traditional pregnancy registries 
for any medicinal product. 
To date, there is no harmonized definition of terms related to pregnancy exposure, 
definition of retrospective and prospective cases as well as minimum required data for 
identification of major malformations (10). Therefore, harmonized metrics and measure 
for data collection and analysis could provide efficient data collection and evaluation of 
the risk of reproductive toxicity. In this regard, we are aware of an Innovative Medicine 
Initiative (IMI) project called Continuum of Evidence from Pregnancy Exposures, 
Reproductive Toxicology and Breastfeeding to Improve Outcomes Now (ConcePTION) 
(24). The IMI ConcePTION project is public-private partnership to address this problem. 
The aim of ConcePTION is “Building an ecosystem for better monitoring and 
communicating safety of medicines use in pregnancy and breastfeeding: validated and 
regulatory endorsed workflows for fast, optimized evidence generation” 
Limitation of the this approach 
Data used in PRIM were the pregnancy cases reported to the company that were primarily 
reports from patients and healthcare professionals or other spontaneous post-marketing 
sources, but also include patients from clinical trials and non-interventional studies who 
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did not participate in the Registry. The limitations of PRIM are consistent with the well-
known limitations of voluntary post marketing report systems (e.g, under reporting, 
potentially more missing or incomplete information than in a study) (25–27).  
Bias that may occur when outcome information is known prior to reporting was reduced 
by excluding retrospective cases (i.e., pregnancies reported after the pregnancy outcome 
is known) from PRIM. However the definition of a prospective pregnancy report may also 
introduce a bias and a deviation between the PRIM results and those of other data 
sources using other conventions. In PRIM the definition of prospective and retrospectives 
cases specified by EMA guidance has been used but collection of sufficient data from 
cases should be attempted to allow alternative definitions to be constructed in parallel for 
sensitivity analysis. This has proved to be a difficulty in the current dataset due to the 
constraints of the global database structure (which is based on the ICH E2B R2 data 
model) (28) and will need further development. Although the prevalence estimates of 
congenital malformation in PRIM appear to be in line with estimates from external 
reference general populations, a direct comparison between PRIM and external 
references are hampered by differences in spontaneous reporting and registry data 
collection. Nevertheless the results can be put in context with a range of estimates from 
the general population coming from different data sources with a focus on those which 
use similar data collection methods as PRIM. 
To reduce the potential for selection bias due to loss to follow-up (a recognized limitation 
of voluntary reporting systems), contact attempts via multiple contact modalities were 
systematically and repeatedly performed under the PRIM processes, however this needs 
further improvement.  
Performing long-term FU (3 month and one year) has operational challenges for voluntary 
post marketing data. Initiation and completion of long-term follow-up is a considerable 
resource activity. In addition, in the targeted FU checklist some data can be collected from 
a primary reporter but other data (e.g. health and development status of the baby) 
ultimately require referral to other stakeholders (e.g. pediatrician) which in turn requires 
consent; currently there is no complete guideline for Industry to get information from such 
sources. 
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Conclusion 
Using enhanced pharmacovigilance of spontaneously reported data, the PRIM process 
applies intensive monitoring of maternal drug exposure during pregnancy, prospective 
collection of critical safety data, and structured programming of data to estimate 
prevalence of major malformations and other pregnancy outcomes. This was applied to 
fingolimod data but could be adapted for use with a wide range of medicinal products. 
Use of the large volume of pregnancy data in industry pharmacovigilance databases and 
the achievement of sufficient data quality can qualify PRIM as a feasible alternative to 
costly and often lengthy pregnancy registries. 
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7. Discussion  
7.1 Contribution of this thesis 
There is an unmet need for evidence-based, current and accurate information on safety 
of drug during pregnancy. Speed of generating sufficient high-quality evidence is vital 
which may assist for medicine label update and informing HCP and patient. Currently 
data collection and analysis of human pregnancy safety is at best inefficient, at worst 
inadequate and incomplete, thus the prescribing guidance and pack insert are in fact non-
informative. Diseases with low or very prevalence inevitably lead to low exposure 
numbers, particularly in pregnancy, which in turn results in a low sample size for study 
and evaluation. One study reported that enrollment and retention in 34 US pregnancy 
registries were lower relative to the manufacturer’s capture of spontaneous reports for 
exposed pregnancies (61). The authors suggested a need for worldwide safety data 
collection of pregnancy exposures in order to achieve an adequate cohort of exposed 
pregnant women to support meaningful medical and statistical analyses; this is 
particularly important for products that are rarely used by pregnant women. 
Examples of additional approaches that go beyond routine pharmacovigilance to 
capturing case reports of pregnancy exposures include (61): 
1. Enhanced pharmacovigilance strategies with follow-up questionnaires directed to 
exposed pregnant women who do not choose to enroll in formal registries; 
2. Population-based networks that capture birth defects and matched controls, and 
3. Population-based studies employing mother–baby linkages in reimbursement 
claims or electronic medical records (61) 
We established a method of enhanced pharmacovigilance by using an industry-based 
global post-marketing safety database to access pregnancy-specific safety data for 
prospective case reports. Due to slow enrollment in pregnancy registry, alternative 
method is required for the provision of appropriate and up-to date safety information in a 
timely manner for better decision-making. This method is called PRIM (PRegnancy 
outcome Intensive Monitoring) to increase the amount of data with which to evaluate the 
risk of reproductive toxicity for fingolimod (Gilenya®). The PRIM process applies intensive 
monitoring of maternal drug exposure during pregnancy, prospective collection of critical 
safety data, and structured programming of data to estimate prevalence of major 
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congenital malformations and other pregnancy outcomes. This was applied to fingolimod 
data but could be adapted for use with a wide range of medicinal products.  
It is my view that this is a significant enhancement to routine pharmacovigilance because 
diseases such as MS require careful medical assessment of the benefits and risks of 
continuing medical treatment during pregnancy. This assessment should, of course be 
inclusive of the patient, and there should be an open discussion of the evidence and any 
concerns. 
The main strengths and advantages of the PRIM process are that this systematic series 
of controls assure the achievement of good data quality thereby optimizing the value and 
utility of the large volume of pregnancy data in the Novartis pharmacovigilance database.  
This is illustrated by the implementation of the PRIM process for fingolimod. As a direct 
result, the PRIM dataset included a large cohort of pregnancy exposures.  Almost six 
times as many spontaneous reports (674 prospective cases) of pregnancy exposures to 
fingolimod were received in four years when compared to prospective pregnancies (113 
cases) enrolled into the pregnancy registry in seven years (98). On this basis the PRIM 
method could be complementary to, or potentially an improved alternative, to traditional 
pregnancy registries for any medicinal product where close monitoring of pregnancy 
exposures and outcomes is required. 
There is a need to make better scientific use of existing PV systems to collect the best 
possible data on pregnancy exposures and outcomes, thereby to facilitate the medical 
and scientific evaluation process. Enhanced pharmacovigilance methods such as the 
PRIM can support the provision of evidence-based information in a timely manner that 
will in turn enable patients and HCPs to make informed decisions. 
Another important area that was investigated in this research project was concerning the 
behaviors of HCPs and pregnant patients in relation to prescribing and use of medicines 
during pregnancy. The fast-changing and ever expanding technological landscape brings 
new capabilities for information provision relating to the safety of medicines and there is 
ever-increasing use of the internet to seek and find medical information. Patients, carers 
and HCPs have adopted social media platforms and forums to discuss their experiences 
of medication use. The IMI Web-RADR project has explored the value of online 
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exchanges through social media and has developed a mobile application for identifying 
adverse events in order to aid signal detection. The WEB-RADR project also developed 
a novel algorithm for adverse event recognition and text-mining in social media (91,92). 
This consortium agreed that general social media such as Facebook and Twitter are not 
recommended for broad statistical safety signal detection, however these channels may 
be a useful asset to PV activity in specific areas including exposure to medicines during 
pregnancy (92).  
I adopted the WEB-RADR machine learning technique to characterize posts acquired 
from pregnancy-related online forums where patients discussed MS medications using 
WEB-RADR tools. Approximately 80% of all relevant posts were representative of 
personal experiences with MS medications. Individuals shared the reasons behind their 
personal decisions regarding treatment; some patients described how they felt after 
changes in therapy: other described experiences when they switched, started, or stopped 
medication, and whether this change in treatment was because of an HCP’s 
recommendation or because of the patient’s personal beliefs. 
Data from this study showed that pregnant patients were evidently seeking information 
online related to the risk associated with their disease (e.g. MS relapse during pregnancy 
or postpartum). A cohort of patients queried the safety profile of one or more medications 
in pregnancy. Certain patients asked about when to restart medical treatment postpartum, 
and somewhat linked to this raised questions about breastfeeding whilst taking 
medication (85). Last, but not least, there was a significant number of social media users 
who provided advice to others about decisions and outcomes or based on their own 
personal experiences when taking a specific medication (85). It remains to be determined 
whether such advice is appropriate, consistent with the available evidence across a wider 
cohort, or if it is well-informed and up to date. There certainly appears to be some 
evidence that personal experiences as reported by social media users are trusted by the 
recipients of such anecdotal information. 
Overall, the results emphasize that patients and carers are willing to share personal data 
in social media threads and within online fora. In my view, more effort should be made to 
engage pregnant mothers and their family members or carers in active medical research 
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targeted at informing them about the purpose of pregnancy registries and teratology 
information programmes. Ideally, the sponsors of clinical research programmes should 
set the expectation for participants that either at the end of a study, or when a registry is 
complete, all important safety findings, and, if possible, an overview of the overall results, 
should be shared with the contributors. 
When a woman is pregnant or breastfeeding and she may need therapeutic treatment the 
decision is complex as she is taking medication ‘’for two’’. Ultimately, it is for the mother 
to decide for herself and her unborn baby by weighing the benefits versus the potential 
risks of medical treatment. In order to make an informed decision, some mothers rely on 
the attending physician’s advice and approved product labelling e.g. the summary of 
product characteristics, pack insert or patient information leaflet. Each one of these 
documents is based on scientific evidence. The problem is that in relation to pregnancy 
exposures and outcomes that evidence is often missing, very often incomplete, and 
sometimes unreliable as it is unknown if reproductive toxicology outcomes in animal 
models translate to human mothers and their offspring. A study reviewed medication risks 
during pregnancy for 172 drugs approved by the FDA between 2000 and 2010. Amongst 
these medicinal products, in 97.7% of drugs, the teratogenic risk in human pregnancy 
was classified as undetermined, and the amount of data for 73.3% of these drugs was 
described as none (30). In my view, this shows a significant lack of information to protect 
the public’s health. There is a need to coordinate efforts from all stakeholders (see Figure 
5) to collect more data, perform formal analysis in a regular basis and to update medicine 
labels on current evidence. 
My analysis of the risk of cleft lip and/or palate associated with anticonvulsant medicines 
was conducted using the evidence from two large post-marketing safety databases (99). 
In addition, I performed an evaluation of the completeness of safety information provided 
in the approved product labels for prescribers and patients in order to optimize informed 
decision-making. The results of the disproportionality analysis from the FAERS database 
showed that twelve antiepileptic drugs were statistically associated with risk of cleft lip 
and palate (74). The risk of cleft is described in the regulatory agency-approved labeling 
for valproate, topiramate, carbamazepine, and phenytoin in both the UK and the USA (74) 
and the information provided was consistent with the literature. It was observed that there 
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were important differences in the information content presented to prescribers in the UK 
and US such as a product being contraindicated in one location but not in the other, and 
precautionary measures being provided in one country but a distinct lack of the same 
information being available in the other. In my view, these constitute clear discrepancies, 
and this constitutes a significant problem for recipients of the information, in that it has 
the propensity to cause doubt, and perhaps even to engender a lack of trust in both the 
MAH and the health authority that approved the label. Other studies have reported 
inconsistencies in defining and reporting the foetal risk category/assessment among 
different drug regulatory authorities in different counties (100–102). Taken in their totality 
these discrepancies and inconsistencies create confusion, particularly for patients and 
carers who travel between the two countries. Moreover the discrepancy concerning the 
absolute contraindication could well affect prescribing decisions in the two countries. I 
believe that there is a need to improve the communication of the safety profiles of 
medicines used in pregnancy via standardization and inclusion of information in 
medicines labels and package insets. In addition, patients and HCPs should be informed 
more proactively and efficiently how to access, interpret and act on comprehensive 
information which should be harmonised and provided in its most complete and up-to-
date form. 
7.2 History repeats itself – some parallels between sodium valproate- induced birth 
defects and thalidomide? 
Sodium valproate provides another example of a lack of a harmonised, systematic 
approach to inform for patients and HCPs in a timely manner about important safety 
concerns related to the outcomes of exposures in pregnancy. This goes far beyond the 
provision of comprehensive, current, evidence-based labeling information; and, in my 
opinion, has led to catastrophic results in the offspring of mothers treated with this drug. 
Sodium valproate or valproic acid has approved indications in multiple European 
countries various for treatment of epilepsy, bipolar disorder and migraine (103). For some 
patients with serious conditions, valproate may be the best or only treatment option (104). 
However, it has long been known that if taken during pregnancy valproate affects the 
unborn baby and is strongly associated with a specific pattern of congenital anomalies in 
around 10% of neonates (104). Maternal exposure to valproate is known to cause specific 
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birth defects such as spina bifida, cleft lip and palate, malformations of the limbs, heart, 
kidney, urinary tract and sexual organs, and neurodevelopmental delay (104). Even more 
significant is the more recently gathered evidence that the most significant concern 
associated with valproate exposure in utero is the occurrence of neurodevelopmental 
delay in around 40% of the offspring (104). Due to the long latency of the appearance of 
autism or low IQ in children these anomalies are not detectable at birth (105). 
The term Fetal Valproate Syndrome was first suggested by DiLiberti et al. in 1984, 
following publication of a case series (106). This term refers to a pattern of anomalies in 
infants exposed to valproate. Typical facial dysmorphias were reported to include 
trigonocephaly, tall forehead with bifrontal narrowing, epicanthic folds, infraorbital groove, 
medial deficiency of eyebrows, flat nasal bridge, broad nasal root, antiverted nares, 
shallow philtrum, long upper lip and thin vermillion borders, thick lower lip, and small 
downturned mouth (107). The authors also reported the occurrence of developmental 
disorders in children born to women who took valproate during pregnancy.  
Three decades later, following a review in 2013, the EMA recommended restrictions to 
the use of valproate. The product information for all formulations of valproate was updated 
and educational materials were developed for healthcare professionals and patients. 
These included a guide for prescribers, a patient booklet, an acknowledgment of risk form 
and a letter to inform healthcare professionals. However, just a few years later the French 
national competent authority, ANSM (Agence Nationale de Sécurité du Médicament et 
des Produits de Santé, which is the French Agency for the Safety of Health Products), 
has suggested that these measures have not had the desired effect. 
On 26 September, 2017, the EMA’s Pharmacovigilance Risk Assessment Committee 
(PRAC) held its first public hearing to discuss the safety of the use of valproate during 
pregnancy (104,108). Whilst public hearings have been a part of the regulatory process 
outside of Europe this was a bold experiment aimed at improving transparency in public 
health topics relevant to safety. The hearing was planned to determine the adequacy of 
current warnings, precautions, and prescribing restrictions concerning adverse outcomes 
in babies born to women who take valproate during pregnancy. Members of the public 
such as patients and their mothers, as well as expert health care professionals, a 
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representative of industry, the mass media and journalists across the EU were invited to 
attend and express their view to the PRAC on the following three questions:   
1. What are EU citizens’ views of the risks of taking valproate during pregnancy,
including its potential effects on the child?
2. What are their views on the measures currently in place to reduce the risks of using
valproate during pregnancy?
3. What other measures should be taken to reduce the risks of using valproate during
pregnancy?
The full recording of public hearing is available online at 
https://www.youtube.com/watch?v=07LlmEpwY9g&feature=youtu.be . (109) 
The Public Hearing provided the PRAC with a very transparent means to gather the 
public’s views and concerns, particularly where regulatory actions were being considered 
in a wider public health context (110). For example, here are two patients who shared 
their concerns during the public hearing. 
 Epilepsy patient and mother of three valproate-affected children 
Photo taken from the EMA video recording of public hearing, YouTube record available at https://www.youtube.com/watch?
v=07LlmEpwY9g&feature=youtu.be, Accessed online Oct.2019. 
• “I am a mother of three adult children affected
by valproate...and we have a number of important
concerns...”;
• “Many patients receive their medications in
plastic bags...without any original patient leaflets or
pack inserts...”;
• “Educational Materials can only be found online
and are not printed or distributed sufficiently... [By the
manufacturer]” (109).
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Epilepsy patient and mother of valproate-affected child 
Photo taken from the EMA video recording of public hearing, YouTube record available at https://www.youtube.com/watch?
v=07LlmEpwY9g&feature=youtu.be,  Accessed online Oct 2019. 
“...In France they are developing an on-box warning (visual warning) this is what we have 
in the UK (right side) as you can see there is a very big difference!”(109) 
In addition to the two detailed histories shared by these patients, I observed several more 
key messages confirming that patients (mothers, and indeed both parents) and carers 
require clear communication, for example (selected quotations from the evidence 
presented in the public hearing) (109): 
• “I took ‘Epilim’ (brand name) not sodium valproate (generic name)...”
[Interpretation: patient had not been informed and did not understand from the
pack insert that the active ingredient of ‘Epilim’ is valproate; key learning:
prescribing doctor or pharmacist or nurse should have explained about the active
ingredient of ‘Epilim’ and warned the patient about potential adverse effects on the
fetus if the patient was pregnant]
• “No educational booklets available - vital information are missing...”
[Interpretation of statement: Educational material was not available in
pharmacies/key learning: better distribution system and even digital solution is
required for global access of safety information]
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As a result of the public hearing, the PRAC and the EMA provided new measures for 
comprehensive risk minimization, including the following (111):  
• A pregnancy prevention programme (PPP); 
• Visual warning(s) about the risk in pregnancy in the outer packaging; 
• A new risk acknowledgement form for patients; 
• Updated, clear and comprehensive educational materials for patients and HCPs 
In the valproate pregnancy prevention programme, HCPs are instructed to assess each 
patient’s potential for becoming pregnant by evaluating their individual circumstances and 
then assist their patients in making informed decisions. HCPs are responsible for 
informing their patients about the use of effective contraception methods throughout the 
administration of valproate, and to review all such treatments at least annually. Overall, 
the public hearing led to better safety recommendations, tailored to meet the real needs 
and problems of patients, which were identified at the hearing (110). It allowed different 
stakeholders to listen to and learn from each other. 
However, much of the discussion related more to healthcare professionals’ actions and 
less to what the PRAC can influence. Furthermore it was mentioned that several of the 
issues under consideration needed to be implemented at national level, rather than by 
EMA.  In my view, the public hearing didn’t provide a complete solution to the current gap 
of risk mitigation and communication. There remains a significant concern about what 
harmonised actions, if any, should be taken at a global level concerning the risks to the 
embryo and fetus from valproate. Legislation differs from country to country in terms of 
medicines dispensation and prescribing, but all countries have an obligation to protect 
public health. There remains a genuine concern that children of patients treated with 
valproate may still suffer congenital anomalies and/or neurodevelopmental disorders, 
simply because of the differences in regulations when an international border is crossed. 
Another important issue is restrictions in the use of valproate practically in the secondary 
indications such as migraine and bipolar disorder (104) where clearly the risks outweigh 
the benefits for use in a vulnerable population.  
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8. Conclusion 
Data collection, collation and analysis concerning pregnancy exposures and outcomes is 
disparate and fragmented. As a direct consequence the provision of timely, evidence-
based, comprehensive information via product labels is lacking, or at best woefully 
inadequate. Whilst there have been some positive steps taken in the last decade, 
including  risk characterization, the provision of tools for risk minimization during 
pregnancy, and the inauguration of pregnancy prevention programmes, much work 
remains to be done. 
Optimization of existing pharmacovigilance systems for the collection, processing 
(including follow-up) and analysis of pregnancy reports such as it is presented in the PRIM 
programme could be a starting point for standardization and harmonization. This in turn 
could lead to novel methods for prompt qualitative and quantitative signal detection. As 
always where spontaneous prospective reporting is involved there is a clear requirement 
for high quality data, particularly concerning the timings of exposure to medicines, and 
precision when reporting the outcomes for both mother and neonate(s). When data are 
available, there is a need for more transparent, faster, and harmonized evaluations 
according to aligned medical assessment standards. Last, but not least, open source 
tools should be adopted for communicating information on the safety of medicines during 
pregnancy and breastfeeding with HCPs, patients and all other stakeholders in 
pharmacovigilance. Moreover, there is an imperative to ensure that there is a life-cycle 
process implemented for data collection, collation, processing, and evaluation to support 
real-time decision making concerning the benefits and risks of medicines and how to 
maintain optimal lines of communication of new information to stakeholders. It is also 
vitally important to consider providing consolidated recommendations across whole 
regions or continents, aiming for the widest possible outreach. Digital solutions should be 
considered, such as mobile applications (app) and social media platforms which support 
patients, carers and prescribers in order to raise awareness. I would also advocate the 
adoption of two-way communication between the pharmaceutical industry and patients 
for better exchange of safety information. 
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I believe that the chances of successful progress towards a better future can only be 
improved by dedicating resources (human, financial and technological) to a pre–
competitive environment with close collaboration between all stakeholders.  
It would be a very positive step for the scientific community to collaborate more closely 
with pregnant patients and their families, in order to establish trust and goodwill. All 
stakeholders including HCPs, regulators, pharmaceutical companies, Teratology 
Information Services (local, national or regional) and other members of the society should 
work together to gain mutual understanding and share data to address information needs, 
and provide tangible solutions.  
9. Direction of future research 
The safety of medicinal products administered during pregnancy and lactation is a 
complex topic. In my opinion, there are multiple areas that require further research:   
 
• Streamlining and maximising the efficiency of data collection, from first exposure 
to medicine(s) to birth and beyond, particularly where there is a potential for 
neurodevelopmental delay. There is a clear and obvious need for more active 
surveillance perhaps using apps combined with wearables, or approved medical 
devices that collect, normalise and transmit data to a secure repository; 
• Defining a set of common data fields should be established to standardise the 
content, providing detailed specifications for each field, such a field length, data 
type, units of measurement, etc.; 
• Development of a common data model should be prepared in order to support the 
pooling of data from as many different sources as possible, from early 
development through to post-marketing, and perhaps even including over-the-
counter medicines; 
• Determining how best to use the common data model by pool data to increase 
statistical power and cover greater population diversity linking existing fragmented 
data sources such as product-specific pregnancy registries, disease registries, 
pharmacovigilance systems (at multiple levels within MAHs, as well as in National 
Competent Authorities e.g. Swissmedic, Regional Authorities e.g. EMA and in 
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Global Non-Governmental Organisations e.g. WHO Uppsala), and Teratology 
Information Units; 
• Improving analytical methods used for evaluating the statistical significance of 
findings for example by testing the application of proven statistical methods (e.g. 
disproportionality analysis) to aid medical assessment; 
• Using all of the above to inform decisions that impact the health of women and 
their children who were exposed to medicines in utero; 
• Harmonising, at a global level, timely and appropriate communication of those 
decisions, and: 
• Supporting those communications with reference materials that accurately reflect 
the evidence as well as providing educational materials covering the use of 
medication in pregnancy and breastfeeding.  
Beyond pregnancy, information concerning the safety of medicines used during 
breastfeeding is largely missing. There is lack of appropriately qualified animal models to 
predict levels of medicinal products (active pharmaceutical ingredients and metabolites) 
in breast milk. Furthermore there is a very limited biobank of human breast milk donated 
by nursing mothers that would enable research in this field (112). 
In closing my thesis I want to emphasize that there is hope! I am aware that the 5-year 
Innovative Medicine Initiative (IMI) project called Continuum of Evidence from Pregnancy 
Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now 
(ConcePTION) is planning to explore these above mentioned research areas (113). The 
IMI ConcePTION project is a collaboration between public-private partners and the 
pharmaceutical industry to address this problem. The aim of ConcePTION is: 
“Building an ecosystem for better monitoring and communicating safety of medicines use 
in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, 
optimized evidence generation” (113). 
The IMI ConcePTION provides a mechanism with the potential to address the burning 
platform for the development of a stronger framework and improved approaches to 
consolidating the evidence from case reports of exposures to medicines during pregnancy 
and the related outcomes. I believe that all MAHs have a moral, ethical and legal 
obligation to reduce the level of uncertainty affecting prescribing decisions. Improved 
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information will help both HCPs and pregnant mothers to make better-informed important 
decisions which relate to either taking potentially essential medical treatment(s) and 
protecting the unborn child.  
Last but not the least, concerns have arisen that paternal drug exposure prior to 
conception may also contribute to: 
• Changes in fertility (114,115); 
• Adverse pregnancy outcomes (51),or  
• Birth defects (116) 
Further research is need regarding paternal drug exposure and risk mitigation strategies. 
This could be almost fully informed by first researching and communicating the results 
from the topics itemised above. 
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